

**Prospective, Randomized, Multi-center Trial of Initial Trophic Enteral Feeding Followed by Advancement to Full-Calorie Enteral Feeding vs. Early Advancement to Full-Calorie Enteral Feeding in Patients with Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)**

**and**

**Prospective, Randomized, Blinded, Placebo-controlled, Multi-center Trial of Omega-3 Fatty Acid, Gamma-Linolenic Acid, and Anti-Oxidant Supplementation in the Management of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)**

**ARDS Clinical Network  
ARDS Network Study # 07  
Protocol Version II**

November 14, 2008

# TABLE OF CONTENTS

ABBREVIATIONS .....	6
PART I .....	7
STUDY SUMMARY .....	7
PART II .....	11
STUDY DESCRIPTION.....	11
1 BACKGROUND .....	11
1.1 INFLAMMATION IN ALI / ARDS .....	11
1.2 ENTERAL NUTRITION IN CRITICAL ILLNESS.....	12
1.3 TIMING OF ENTERAL NUTRITION .....	12
1.4 VOLUME OF ENTERAL NUTRITION AND TROPHIC FEEDS.....	13
1.5 SUMMARY OF ENTERAL NUTRITION .....	15
1.6 FATTY ACID METABOLISM IN ALI/ARDS .....	15
1.7 CYCLOOXYGENASE AND LIPOXYGENASE METABOLITES .....	16
1.8 OMEGA-3 FATTY ACIDS AND CYTOKINE MEDIATORS .....	17
1.9 HUMAN CLINICAL STUDIES OF OMEGA-3 FATTY ACIDS IN INFLAMMATORY DISEASE ...	18
1.10 HUMAN STUDIES OF OMEGA 3 FATTY ACIDS IN ALI/ARDS.....	19
1.11 GAMMA-LINOLENIC ACID AND OMEGA THREE FATTY ACIDS .....	19
1.12 SUMMARY OF OMEGA-3 FATTY ACIDS AND ALI / ARDS .....	20
1.13 OXIDATIVE STRESS AND ARDS .....	20
1.14 CALORIC RESTRICTION, ENERGY EXPENDITURE, AND OXIDATIVE STRESS.....	21
1.15 NUTRITION AND OXIDATIVE STRESS .....	21
1.16 SUMMARY OF ANTI-OXIDANTS AND ALI / ARDS .....	21
1.17 MEASUREMENT OF LONG TERM OUTCOMES AND ACUTE LUNG INJURY .....	22
2 OBJECTIVES .....	22
2.1 PRIMARY OBJECTIVES .....	22
2.2 SECONDARY OBJECTIVES .....	23
2.3 PRIMARY HYPOTHESES.....	23
2.4 SECONDARY HYPOTHESES .....	23
3 END POINTS .....	24

3.1 PRIMARY ENDPOINT .....	24
3.2 SECONDARY ENDPOINTS .....	25
3.3 OTHER ENDPOINTS .....	25
4 STUDY POPULATION AND ENROLLMENT .....	26
4.1 NUMBER/SOURCE/SCREENING.....	26
4.2 INCLUSION CRITERIA .....	27
4.3 EXCLUSION CRITERIA.....	27
4.4 ENROLLMENT, RANDOMIZATION, AND STUDY INITIATION TIME WINDOW .....	28
4.5 INFORMED CONSENT.....	29
4.6 RANDOMIZATION .....	29
4.7 MINORITIES AND WOMEN AND CHILDREN .....	29
5 STUDY PROCEDURES .....	30
5.1 ENTERAL FEEDING PROCEDURES.....	30
5.1.1 Enteral Feeding Formula .....	30
5.1.2 Enteral Feeding Site.....	30
5.1.3 Enteral Feeding Rates.....	30
5.1.4 Gastric Residuals.....	31
5.1.5 Patient Position .....	32
5.1.6 Holding or Interrupting Enteral Feeds .....	32
5.1.7 Gastrointestinal Intolerances.....	32
5.1.8 Completion of Enteral Feeding Procedures.....	34
5.1.9 Premature Withdrawal from Treatment.....	35
5.2 COMPOSITION OF THE N-3 FATTY ACID / GLA / ANTI-OXIDANT SOLUTION (STUDY EMULSION) .....	35
5.3 ADMINISTRATION OF THE STUDY SOLUTION (OR PLACEBO) .....	36
5.4 BLINDING OF STUDY EMULSION OR PLACEBO TREATMENT .....	37
5.5 GLUCOSE CONTROL .....	37
5.6 VENTILATOR PROCEDURES .....	37
5.7 ON-STUDY FLUID MANAGEMENT .....	37
5.8 PROCEDURES AFTER RE-INTUBATION .....	38
6 DATA COLLECTION .....	38
6.1 BACKGROUND ASSESSMENTS .....	38

6.2	BASELINE ASSESSMENTS .....	38
6.3	ASSESSMENTS DURING STUDY .....	39
6.4.	ASSESSMENTS AFTER HOSPITALIZATION .....	41
6.5	OTHER DATA COLLECTED.....	42
6.6	ENDPOINT DETERMINATIONS .....	43
7	STATISTICAL CONSIDERATIONS .....	43
	PRIMARY ENDPOINT .....	43
	SECONDARY ENDPOINTS.....	45
	PHASE 1 PHARMACOKINETICS .....	46
8	DATA COLLECTION AND SITE MONITORING .....	47
8.1	DATA COLLECTION.....	47
8.2	SITE MONITORING .....	47
9	RISK ASSESSMENT .....	47
9.1	RISKS OF ENTERAL FEEDINGS .....	47
9.2	RISKS OF FULL-CALORIE ENTERAL FEEDINGS .....	48
9.3	RISKS OF TROPHIC ENTERAL FEEDINGS .....	48
9.4	RISKS OF OMEGA-3 FATTY ACIDS.....	48
9.5	RISKS OF GLA.....	48
9.6	RISKS OF ANTI-OXIDANTS .....	49
9.7	RISKS OF BLOOD DRAWS.....	49
9.8	RISK OF DEATH .....	49
9.9	MINIMIZATION OF RISKS .....	49
9.10	POTENTIAL BENEFITS .....	50
9.11	RISKS IN RELATION TO ANTICIPATED BENEFITS .....	50
10	HUMAN SUBJECTS.....	51
10.1	SELECTION OF SUBJECTS .....	51
	10.1.1 <i>Equitable Selection of Subjects</i> .....	51
10.2	INFORMED CONSENT .....	51
10.3	CONTINUING CONSENT .....	52
10.4	IDENTIFICATION OF SURROGATES .....	52
10.5	JUSTIFICATION OF SURROGATE CONSENT .....	52

10.6 ADDITIONAL SAFEGUARDS FOR VULNERABLE SUBJECTS .....	53
10.7 CONFIDENTIALITY .....	53
11 ADVERSE EVENT REPORTING.....	54
11.1 CLINICAL OUTCOMES .....	54
11.2 ADVERSE EVENT REPORTING TIMELINE .....	55
APPENDICES .....	56
<i>A Identification of Ventilator-Associated Pneumonia</i> .....	56
<i>B Exclusion Definitions</i> .....	57
<i>C Trophic Feeding Protocol</i> .....	59
<i>D Full-calorie Feeding Protocol</i> .....	60
<i>E Time-Events Schedule</i> .....	61
<i>F Adverse Events</i> .....	62
<i>G Ventilator Procedures</i> .....	64
<i>H Conservative Fluid Management Approach</i> .....	68
<i>I Genetic Testing</i> .....	69
<i>J De-identified Data Elements for Screened, Non-Enrolled Subjects</i> .....	70
<i>K Long Term Outcomes</i> .....	71
<i>L. Data and Safety Monitoring Board</i> .....	76
<i>M. AUDIT Questionnaire</i> .....	77

# ABBREVIATIONS

<b>AA</b> = Arachidonic Acid	<b>NAC</b> = N-acetylcysteine
<b>ALI</b> = Acute Lung Injury	<b>NHLBI</b> = National Heart Lung and Blood Institute
<b>ARDS</b> = Acute Respiratory Distress Syndrome	<b>OR</b> = Odds Ratio
<b>BMI</b> = Body Mass Index	<b>PaCO<sub>2</sub></b> = Partial pressure of arterial carbon dioxide
<b>BUN</b> = Blood Urea Nitrogen	<b>PAI -1</b> = Plasminogen Activator Inhibitor 1
<b>CHF</b> = Congestive Heart Failure	<b>PaO<sub>2</sub></b> = Partial pressure of arterial oxygen
<b>CPAP</b> = Continuous Positive Airway Pressure	<b>PAP</b> = Pulmonary Artery Pressure
<b>CPR</b> = Cardiopulmonary resuscitation	<b>PB</b> = Barometric Pressure
<b>CT</b> = Computed Tomography	<b>PBW</b> = Predicted Body Weight
<b>DBP</b> = Diastolic Blood Pressure	<b>PCP</b> = <i>Pneumocystis carinii</i> pneumonia
<b>DGLA</b> = Dihomo- $\gamma$ -Linolenic Acid	<b>PEEP</b> = Positive End-Expiratory Pressure
<b>DHA</b> = Docosahexaenoic Acid	<b>PEG</b> = Percutaneous Endoscopic Gastrostomy
<b>DSMB</b> = Data Safety Monitoring Board	<b>PGD<sub>2</sub></b> = Prostaglandin D <sub>2</sub>
<b>EPA</b> = Eicosapentaenoic Acid	<b>PGE<sub>2</sub></b> = Prostaglandin E <sub>2</sub>
<b>FACTT</b> = Fluid and Catheter Treatment Trial	<b>PGI<sub>2</sub></b> = Prostaglandin I <sub>2</sub>
<b>FiO<sub>2</sub></b> = Fraction of Inspired Oxygen	<b>PIN</b> = Personal Identification Number
<b>GCS</b> = Glasgow Coma Scale	<b>PPAR</b> = Peroxisome Proliferator-activated Receptor
<b>GLA</b> = Gamma-Linolenic Acid	<b>Pplat</b> = Plateau pressure
<b>GRV</b> = Gastric Residual Volume	<b>PS</b> = Pressure Support Ventilation
<b>Home</b> = Type of residence immediately prior to study hospitalization	<b>PUFA</b> = Polyunsaturated Fatty Acids
<b>ICU</b> = Intensive Care Unit	<b>ROS</b> = Reactive Oxygen Species
<b>IgA</b> = Immunoglobulin A	<b>SBP</b> = Systolic Blood Pressure
<b>IL-1</b> = Interleukin 1	<b>SBT</b> = Spontaneous Breathing Trial
<b>IL-6</b> = Interleukin 6	<b>SpO<sub>2</sub></b> = Oxygen Saturation
<b>IL-8</b> = Interleukin 8	<b>TNF</b> = Tumor Necrosis Factor
<b>IL-10</b> = Interleukin 10	<b>TPN</b> = Total Parenteral Nutrition
<b>IMV</b> = Intermittent Mechanical Ventilation	<b>TxA<sub>2</sub></b> = Thromboxane A <sub>2</sub>
<b>INR</b> = International Normalized Ratio	<b>TxA<sub>3</sub></b> = Thromboxane A <sub>3</sub>
<b>IVRS</b> = Interactive Voice Response System	<b>VAP</b> = Ventilator-associated Pneumonia
<b>LTB<sub>4</sub></b> = Leukotriene B <sub>4</sub>	<b>VFD</b> = Ventilator-free Days
<b>LTB<sub>5</sub></b> = Leukotriene B <sub>5</sub>	<b>WBC</b> = White Blood Cell
<b>mBW</b> = measured body weight	
<b>n-3 FA</b> = omega-3 Fatty Acids	

# Part I

## Study Summary

- **Titles:** Prospective, Randomized, Multi-center Trial of Initial Trophic Enteral Feeding Followed by Advancement to Full-calorie Enteral Feeding vs. Early Advancement to Full-calorie Enteral Feeding in Patients with Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)  
and  
Prospective, Randomized, Blinded, Placebo-controlled, Multi-center Trial of Omega-3 Fatty Acid, Gamma-Linolenic Acid, and Anti-Oxidant Supplementation in the Management of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)
- **Objectives:**
  1. To assess the safety and efficacy of initial trophic enteral feeding followed by advancement to full-calorie enteral feeding vs. initial advancement to full-calorie enteral feeding management strategies in reducing mortality and morbidity in patients with ALI or ARDS
  2. To assess the safety and efficacy of omega-3 fatty acid, gamma-linolenic acid, and anti-oxidant supplementation in reducing mortality and morbidity in patients with ALI or ARDS
- **Hypotheses:**
  1. Initial trophic feeding followed by full-calorie enteral feeding will improve clinical outcomes (specifically increase the number of ventilator-free days to day 28 and decrease the 60-day, hospital mortality) in patients with ALI or ARDS by reducing systemic inflammation and the number of feeding complications as compared to early, full-calorie enteral feeding.
  2. Omega-3 Fatty Acid, Gamma-linolenic acid (GLA), and anti-oxidant supplementation, as compared to placebo, will improve clinical outcomes (specifically increase the number of ventilator-free days to day 28 and decrease the 60-day, hospital mortality) in patients with ALI or ARDS by attenuating systemic inflammation.
- **Study Design:** Multi-center, prospective, randomized, controlled clinical trials. Patients will be randomized into each of the two trials simultaneously (factorial design).
  1. A maximum of 1000 patients will be enrolled.
  2. Patients randomized to trophic enteral feeds will receive trophic feeding rates (10 cc / hr) for 144 hours prior to being advanced to full-calorie feeding rates which will continue for the duration of mechanical ventilation up to study day 28.
  3. Patients randomized to full-calorie enteral feeds will be advanced to full-calorie feeding rates on initiation of feeding and will continue to receive full-calorie feeds for the duration of mechanical ventilation up to study day 28.

4. Patients will be treated with n-3 fatty acids, GLA, and anti-oxidants or indistinguishable placebo every 12 hours for the shorter of 21 days or the duration of mechanical ventilation.
5. Patients will be followed to the earlier of 60 days or hospital discharge. In addition, vital status will be ascertained at 90 days.

- **Sample Size/Interim Monitoring:**

- 1 This study uses a 2 x 2 factorial design comparing the use of initial trophic enteral feeds followed by advancement to full-calorie enteral feeds versus initial full-calorie feeds and comparing treatment with n-3 fatty acid and anti-oxidant supplementation with placebo in patients with ALI or ARDS. The trial will accrue a maximum of 1000 patients (about 250 patients in each of four groups) providing about 500 patients treated initially with trophic enteral feeds to be compared against about 500 patients treated initially with full-calorie enteral feeds and about 500 patients treated with n-3 fatty acid, GLA, and anti-oxidant supplementation against about 500 patients treated with placebo. This provides 90 % power to detect an absolute difference of 2.25 ventilator-free days assuming a mean of 14 and standard deviation of 10.5 ventilator-free days (data from FACTT study) using a two sided  $p = 0.05$  significance level.
- 2 The principal analysis will be intent-to-treat, based upon randomization assignment.
- 3 Trial progress will be evaluated by an independent Data and Safety Monitoring Board to determine if the study should stop for futility or efficacy. Interim analyses will be conducted after enrollment of approximately 100, 250, 500, and 750 patients. Either comparison may be stopped independently if the difference between the numbers of ventilator-free days for the two treatments is greater than the O'Brien-Fleming boundary. A Pocock boundary will be utilized to monitor for an interaction between the two comparisons.
- 4 The DSMB will also monitor the trial for feasibility. Feasibility parameters will include accrual, the ability to follow the enteral nutrition and ventilator protocols, separation of the enteral feeding groups based on volume delivered data, and the frequency of missed doses of the omega-3 fatty acid / GLA / anti-oxidant or placebo supplementation. If any of these parameters indicate that the trial is not feasible, the trial will be modified or terminated.
- 5 The trial will also be monitored by the DSMB for safety. Each comparison will be evaluated separately for safety parameters using mortality, vital sign and laboratory data, and adverse event reporting. If any of these parameters indicate to the DSMB that one or more of the interventions are not safe, the comparison of that intervention will be modified or terminated.

- **Inclusion Criteria**

Patients will be eligible for inclusion if they meet all of the below criteria. Criteria 1-3 must all be present within a 24-hour time period:

Acute onset (defined below) of:



1.  $\text{PaO}_2 / \text{FiO}_2 \leq 300$  (intubated). If altitude  $> 1000\text{m}$ , then  $\text{PaO}_2 / \text{FiO}_2 \leq 300 \times (\text{PB}/760)$
2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph. The infiltrates may be patchy, diffuse, homogeneous, or asymmetric
3. Requirement for positive pressure ventilation via endotracheal tube, and
4. No clinical evidence of left-sided cardiac failure to account for bilateral pulmonary infiltrates.
5. Intention of primary medical team to enterally feed the patient

The 48-hour enrollment time window begins when criteria 1-3 are met. If a patient meets the first three inclusion criteria but has a PAOP (Pulmonary Arterial Wedge Pressure) greater than 18 mmHg, then the first four criteria must persist for more than 12 hours after the PAOP has declined to  $\leq 18$  mmHg, and still be within the 48-hour enrollment window.

“Acute onset” is defined as follows: the duration of the hypoxemia criterion (#1) and the chest radiograph criterion (#2) must be  $\leq 28$  days at the time of randomization. Opacities considered “consistent with pulmonary edema” include any opacities not fully explained by mass, atelectasis, or effusion or opacities known to be chronic (greater than 28 days). Vascular redistribution, indistinct vessels, and indistinct heart borders alone are not considered “consistent with pulmonary edema” and thus would not count as qualifying opacities for this study.

- **Exclusion Criteria**

1. Age younger than 13 years
2. Greater than 48 hours since all inclusion criteria met
3. Neuromuscular disease that impairs ability to ventilate without assistance, such as cervical spinal cord injury at level C5 or higher, amyotrophic lateral sclerosis, Guillain-Barré Syndrome, or myasthenia gravis (see Appendix B)
4. Pregnant or breast-feeding
5. Severe chronic respiratory disease (see Appendix B for detailed exclusion criteria).
6. Burns greater than 40% total body surface area
7. Malignancy or other irreversible disease or condition for which 6-month mortality is estimated to be greater than 50% (see Appendix B).
8. Allogeneic bone marrow transplant in the last 5 years
9. Patient, surrogate, or physician not committed to full support (Exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest).
10. Severe chronic liver disease (Child-Pugh Score of 11-15)
11. Diffuse alveolar hemorrhage from vasculitis.
12. Morbid obesity ( $> 1\text{kg}/\text{cm}$  body weight)
13. No consent/inability to obtain consent

14. Unwillingness or inability to utilize the ARDS network 6 ml / kg PBW ventilation protocol
  15. Moribund patient not expected to survive 24 hours
  16. No intent to obtain central venous access for monitoring intravascular pressures.
  17. > 72 hours since mechanical ventilation initiated
  18. Refractory shock (See Appendix B)
  19. Unable to obtain enteral access
  20. Presence of partial or complete mechanical bowel obstruction, or ischemia, or infarction
  21. Current TPN use or intent to use TPN within 7 days
  22. Severe malnutrition with BMI < 18.5 or loss of > 30% total body weight in the previous 6 months
  23. Laparotomy expected within 7 days
  24. Unable to raise head of bed 30-45 degrees
  25. Short-bowel syndrome or absence of gastrointestinal tract
  26. Presence of high-output (> 500 cc/day) enterocutaneous fistula
  27. INR > 5.0 or platelet count < 30,000 / mm<sup>3</sup> or history of bleeding disorder
  28. Intracranial hemorrhage within the previous month
  29. Allergy to enteral formula, n-3 fatty acids, gamma-linolenic acid, vitamin E, vitamin C, beta-carotene, taurine, or L-carnitine
  30. Requirement for, or physician insistence on, enteral formula supplemented with omega-3 fatty acids (ex: Oxepa®, Impact®) or providing omega-3 fatty acid, GLA, or anti-oxidant supplementation
- **Enrollment and Study Initiation Time Window:** All patients must be randomized within 48 hours of meeting inclusion criteria and within 72 hours of initiating mechanical ventilation. The first three inclusion criteria may be met at either the Network or referring hospital. Following randomization, the low tidal volume protocol for mechanical ventilation must be initiated within one hour (if not already being utilized). Enteral feeds and the enteral feeding protocol must be initiated within 6 hours of randomization. The first dose of n-3 fatty acid / GLA / anti-oxidant supplementation or placebo must be administered within 6 hours of randomization.
  - **Efficacy:** Primary efficacy variable is ventilator-free days to study day 28. Ventilator free days (VFDs): the number of days after initiating unassisted breathing to day 28 after randomization, assuming a patient survives for at least two consecutive calendar days after initiating unassisted breathing and remains free of assisted breathing. This is a composite endpoint reflecting days free of mechanical ventilation to day 28 and mortality. Patients who die before day 28 have zero VFDs.
  - **Secondary Efficacy Variables:**
    1. The secondary efficacy variable is mortality before discharge home, with unassisted breathing to day 60. Patients alive in hospital at day 60 will be considered to have survived.

2. Mortality before hospital discharge home, with unassisted breathing, to day 90. Patients alive in hospital to day 90 will be considered to have survived.
3. Number of ICU-free days at 28 days after randomization.
4. Organ-failure free days to study day 28 (renal, hepatic, central nervous system, hematologic, cardiovascular)
5. Incidence of Ventilator-associated pneumonia

Several other efficacy variables will also be analyzed, as outlined in the protocol.

## Part II

### Study Description

**Prospective, Randomized, Multi-center Trial of Initial Trophic Enteral Feeding Followed by Advancement to Full-calorie Enteral Feeding vs. Early Advancement to Full-calorie Enteral Feeding in Patients with Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)**

and

**Prospective, Randomized, Blinded, Placebo-controlled, Multi-center Trial of Omega-3 Fatty Acid, Gamma-Linolenic Acid, and Anti-Oxidant Supplementation in the Management of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)**  
**Protocol for the NIH ARDS Network**

## 1 Background

The following background sections discuss biochemical effects which many hypothesize as possible mechanisms for the results seen in the phase II data presented. The purpose of this study, however, is to determine the effects on clinical outcomes of the proposed interventions. These changes in clinical outcomes may be the result of the commonly hypothesized mechanisms or may result from other biochemical and/or clinical effects. Many of the proposed secondary outcomes are not meant to definitively establish the underlying mechanisms, but instead will explore biochemical endpoints to provide additional support or generate other hypotheses of how the interventions may result in different clinical outcomes.

### 1.1 Inflammation in ALI / ARDS

Early ALI/ARDS is pathologically characterized by neutrophilic lung inflammation, increased vascular permeability edema (Bernard, 2005; Ware, 2000) and intra-vascular and alveolar fibrin deposition (Idell, 2003; Abraham, 2000). Abundant evidence indicates the cytokines (e.g. tumor necrosis factor (TNF), and interleukin 8 (IL-8)) and the pro-inflammatory and pro-thrombotic

fatty acid derivatives of cyclooxygenase (e.g.  $\text{TxA}_2$ ) and 5-lipoxygenase (e.g.  $\text{LTB}_4$ ) enzyme systems are mediators in the early phase of ALI/ARDS (Caironi, 2005; Gust, 1999; The Acute Respiratory Distress Syndrome Network, 2000). The ARDS network lower tidal volume ventilation trial produced significant clinical benefits, at least in part by reducing the inflammatory cytokine response (Parsons, 2005; The Acute Respiratory Distress Syndrome Network, 2000). It has also been recognized that ALI/ARDS, like severe sepsis, includes an exuberant pro-coagulant response in which fibrin is deposited in small vessels and alveoli (Abraham, 2000; Bernard, 2001; Idell, 2003; Idell, 1989).

## **1.2 Enteral Nutrition in Critical Illness**

Experimental and clinical studies have shown that enteral nutrition has benefits over parenteral nutrition in the critically ill patient. Enteral nutrition has been reported to decrease intestinal bacterial translocation (Runyon, 1994; Wildhaber, 2005), reduce infection rates (Grahm, 1989; Kalfarentzos, 1997; Kudsk, 1992; Moore, F.A., 1992; Moore, F.A., 1989) and preserve gastrointestinal mucosal structure and function (Groos, 1996; Hadfield, 1995) as compared to parenteral nutrition. Clinical studies have shown that these findings translate into better outcomes (Gramlich, 2004; Kalfarentzos, 1997; Kudsk, 1992; Moore, F.A., 1992; Moore, F.A., 1989; Peter, 2005; Taylor, S.J., 1999; Windsor, 1998). However, there is no single standard for enteral nutrition and controversy continues to exist about most aspects of enteral feeding in the critically ill patient.

## **1.3 Timing of Enteral Nutrition**

Recent observational data suggests enteral feeding within 48 hours of initiation of mechanical ventilation is associated with a shorter hospital length of stay and a reduction in mortality in patients with ARDS (Artinian, 2006; Stapleton, 2005). Clinical studies in critically ill surgical patients have reported that beginning enteral feeding early in the ICU and rapidly achieving full-calorie enteral feeding rates decreases infectious complications (Grahm, 1989), shortens hospital stay, decreases hypermetabolism and improves outcomes (Grahm, 1989; Gramlich, 2004; Moore, E.E., 1986; Moore, F.A., 1992; Taylor, S.J., 1999). Unfortunately, these trials were done in narrow sub-populations of critically ill surgical patients, were often not blinded or controlled, did not account for all the enrolled patients, included patients who were not mechanically ventilated, or were confounded by the use of supplemental parenteral nutrition. In addition, the benefits reported in these trials were often not consistently observed. Despite these limitations, these findings have resulted in a recent level II recommendation from the Canadian Clinical Practice Guidelines to initiate enteral feeds within 24-48 hours of ICU admission in all critically ill patients (Heyland, 2003). However, it is difficult to be confident of the findings or extrapolate the results of these studies to the majority of critically ill patients, especially those mechanically ventilated in the medical intensive care unit. Marik and Zaloga (Marik, 2001) performed a meta-analysis of randomized controlled trials that compared enteral feeding initiated earlier or later than 36 hours of hospital admission or surgery in trauma, head-injured, post-operative, burn, and medical intensive care patients. Their analysis showed a significantly lower risk of infection and shortened length of hospital stay in patients who received early enteral nutrition. However, interpretation was limited because of heterogeneity between studies, and none of the studies of medical ICU patients met the quality criteria for inclusion. No significant difference was found in mortality, although vital status data were available for just 40% of the studies.

Furthermore, a large retrospective database review recently found a lower mortality rate in critically ill, non-surgical patients who were fed within 48 hours of initiation of mechanical ventilation compared to those fed after 48 hours (Artinian, 2006). After controlling for all known confounders, the authors found that early enteral feeding was associated with a 20% decrease in ICU mortality and 25% decrease in hospital mortality, despite being independently associated with an increased risk of ventilator-associated pneumonia. Unfortunately, the retrospective nature of the study only allows determination of an association and not a cause and effect relationship.

To further complicate the picture, other clinical studies have shown no benefit to early initiation of enteral nutrition (Eyer, 1993; Ibrahim, 2002; Peck, 2004), and some even a trend towards increased number of infections with early enteral nutrition (Eyer, 1993; Ibrahim, 2002). A quasi-randomized, controlled trial by Ibrahim and colleagues found that early goal enteral feedings in mechanically ventilated medical patients had no effect on mortality, but increased the incidence of ventilator-associated pneumonia, length of ventilation and ICU stay (Ibrahim, 2002). This has caused some investigators to suggest that it is safe and possibly preferable to delay feeding for up to 1 to 2 weeks (Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients, 2002; Koretz, 1995). Unfortunately, these negative studies are also flawed with enrolling relatively small numbers of patients, lacking randomization, only analyzing a subset of the enrolled patients, or utilizing bolus-feeding techniques, which may increase the risk of aspiration.

Despite some consensus guideline recommendations on the acceptability of delaying enteral feeds (Cerra, 1997; Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients, 2002; Koretz, 1995), numerous surveys demonstrate clinician acceptance of the importance of early enteral feeding. Most clinicians report a practice of starting enteral nutrition early in the disease course for critically ill patients. Surveys of actual clinical practice, however, demonstrate that this is rarely the case. In most critically ill patients, enteral nutrition is not initiated for 2-4 days after intubation or ICU admission and many times, enteral feeds are advanced slowly to full-calorie rates over another couple of days (Barr, 2004; De Jonghe, 2001; Heyland, 2004; Heyland, 2003; Preiser, 1999; Rice, 2005). Similar practice occurs within the ARDS network sites. In the recently completed FACTT (National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, 2006) study, only 17% of patients were receiving enteral feeds on day 2 and 20% on day 3. For patients still mechanically ventilated on day 7, only 30% were receiving enteral nutrition.

#### **1.4 Volume of Enteral Nutrition and Trophic Feeds**

In addition to timing, the optimal volume of enteral feedings is also debated. Animal studies demonstrate a trophic effect of low-volume enteral feeding on the intestinal epithelial border. Trophic feeds are generally defined as a small volume of enteral nutrition insufficient for the patients nutritional needs (usually < 25% of daily nutritional needs), but producing some positive gastrointestinal or systemic benefit (Sondheimer, 2004). Compared to enteral feeding abstinence, trophic feedings maintain intestinal microvilli height and structure, stimulate intestinal secretion of brush border enzymes, endogenous peptides, secretory IgA and bile salts, preserve epithelial cell tight junctions, increase intestinal motility and promote intestinal blood flow (Buchman, 1995; Groos, 1996; Hernandez, 1999). These local effects reduce systemic inflammation by helping prevent translocation of bacteria or bacterial products across the

intestinal epithelial barrier and into the circulation (MacFie, 2006). In very low-birth weight infants, minimal enteral nutrition resulted in improved intestinal function and fewer septic complications, ventilator days, and hospital length of stay compared to parenteral nutrition with intestinal abstinence (McClure, 1999; McClure, 2000; McClure, 2002). Despite advocating for early enteral feeds, the Canadian Clinical Practice Guidelines admit the scarcity of data available regarding the optimal volume of early enteral feeds renders making any recommendation impossible (Heyland, 2003). Although the exact volume required to confer these effects in adult humans remains unknown, observational studies in mechanically ventilated patients (many of which did not have ARDS) have found that moderate volumes of feedings are associated with improved clinical outcomes, including lower risk of bloodstream infection (Rubinson, 2004) and lower mortality (Haddad, 2004). Other similarly designed studies have found that low volume feedings are associated with improved outcomes (Dickerson, 2002) in similar populations of critically ill patients. Furthermore, surveys of clinical practice suggest that only 55-75% of daily calories are administered to critically ill patients, even with the use of rigorous protocols (Barr, 2004; De Jonghe, 2001; Heyland, 2004; Heyland, 2003; Rice, 2005; Spain, 1999).

A phase II study comparing early trophic versus early full-calorie enteral feedings in patients requiring mechanical ventilation for at least 72 hours is currently ongoing. Although patients with acute lung injury are included, the study is not restricted to this population. In fact, of the first 100 patients, only 22% had acute lung injury. As a phase II study, the trial is powered to detect differences in biochemical endpoints and large differences in gastrointestinal intolerances, with planned enrollment of 200 patients. The study is progressing well, and an interim analysis evaluating safety, feasibility and separation of treatment arms has been conducted after the first 100 patients have been enrolled. This analysis found that administering trophic and full-calorie feeding rates are both feasible and safe. Patients randomized to the trophic arm received  $220 \pm 139$  cc of enteral feedings per day compared to  $950 \pm 305$  cc for the full-calorie group ( $P < 0.001$ ). These represent 15% and 64% of calculated target feeding rates, respectively. The full-calorie group reaches goal feeding rates on average in 11 hours, with 75% reaching goal rates within 15 hours. Only 4% of the group never reached full-calorie feeding rates. No safety concerns were seen in either group.

The data from these first 100 patients demonstrate that conducting this proposed study is both feasible and safe and have been extremely helpful in informing the proposed ARDS Network design. The final results of this phase II study, however, are unlikely to significantly alter practice or the need for a large, phase III study with important clinical outcomes as endpoints in patients with acute lung injury for many reasons. Like most single center studies, this study is powered to investigate mechanisms (i.e. effect of trophic and full-calorie enteral feedings on systemic inflammation) and is underpowered to detect significant differences in clinically relevant endpoints, such as mortality. This is especially true for patients with acute lung injury, which represent a subset of the population enrolled in the trial. In addition, administration of enteral feeding volumes in mechanically ventilated patients is widely variable in clinical practice without rigorous data supporting one practice over another. Lacking adequate statistical power to investigate clinical outcomes, the phase II study results will contribute to the argument for one practice, but are unlikely to definitively answer the clinical question. Regardless of which arm of the phase II study ultimately results in better biochemical endpoints, clinicians will desire data on the effects of that feeding practice on important clinical outcomes. Although biochemical

endpoints help delineate mechanisms, well-designed, multi-center trials investigating the effects of different volumes of enteral nutrition on clinically important outcomes are needed to direct the standard practice of enteral feeding in patients with acute lung injury. The phase II study, however, has provided important feasibility and safety data and will provide important mechanistic data that will greatly complement the results of the proposed phase III trial.

## 1.5 Summary of Enteral Nutrition

A significant amount of time and resources are spent attempting to deliver enteral nutrition early in a patient's intensive care unit stay. Although there is general consensus that enteral nutrition is preferred over parenteral nutrition, the optimal timing, composition, and amount of enteral feeding is still unknown. Based on data from small surgical studies, some advocate that early enteral feeding improves outcomes in all critically ill patients, while others caution about interpreting the available data in mechanically ventilated, critically ill medical patients. The literature supports both improved and worsened outcomes when critically ill patients are fed as early as possible in their ICU stay, but no studies focus on patients with ALI/ARDS. There is biologic feasibility for both benefit and harm from early, more aggressive feeding, since more complete nutritional support may be accompanied by increased risk of hyperglycemia, uremia, or aspiration. Current practice is heterogeneous, and the reasons for this are uncertain. Further complicating the issue is the paucity of data on the optimal volume of enteral nutrition, especially early in the critical care course. In this trial, we will compare the clinical outcomes and systemic levels of inflammation of critically ill patients receiving initial trophic enteral feedings for 144 hours followed by advancement to full-calorie enteral feedings versus patients receiving initial full-calorie enteral feedings.

## 1.6 Fatty Acid Metabolism in ALI/ARDS

Linoleic and alpha linolenic acid are essential fatty acids classified by their double bond position as n-6 and n-3 fatty acids respectively. Chronic deficiency of these essential fatty acids is associated with a variety of clinical disorders including chronic degenerative neurological disease (Salem, 2001). In addition to their nutritional role, fatty acids profoundly influence inflammatory and immune events by changing lipid mediators and inflammatory protein and coagulation protein expression. After ingestion, n-6 and n-3 fats are metabolized by an alternating series of desaturase and elongase enzymes transforming them into the membrane associated lipids arachidonic acid (n-6), eicosapentaenoic (EPA), and docosahexaenoic (DHA) acids (n-3) respectively (figure 1) (Calder, 2004). All cells contain both n-6 and n-3 lipids but the central nervous system is particularly rich in DHA (Salem, 2001).





Figure 1

Because most humans consume a vast molar excess (>10:1) of n-6 fatty acids and n-6 lipids are the preferred substrate of the rate limiting  $\Delta 6$  desaturase enzyme, arachidonate is the predominant membrane associated fatty acid and is the principal compound released when inflammation induced phospholipase activity liberates membrane associated fatty acids (Simopoulos, 1991). Normally, membrane composition is dynamic reflecting fatty acid intake. In healthy animals and humans the major dietary n-3 fatty acid  $\alpha$ -linolenic acid, is rapidly metabolized and incorporated into plasma and platelets, leukocytes, and endothelial cells (De Caterina, 1994; Fischer, 1983). However, during inflammation, activity of the  $\Delta 5$  and  $\Delta 6$  desaturase enzymes is impaired, limiting the ability to transform membrane content merely by



altering linolenic acid intake (Mandon, 1988). Thus, augmenting n-3 composition during inflammation requires direct supply of the end products EPA and DHA to circumvent what amounts to an effective enzymatic block (Tate, 1989).

During inflammation, fatty acid profiles are abnormal with dramatic decreases in n-3 content. For example, in contrast to the largely preserved levels of n-6 fatty acids, patients at risk to develop ALI/ARDS have been reported to have n-3 levels approaching 25% of those of

normal and those with established ARDS have levels near 6% of normal suggesting a potential role for n-3 replacement (Figure 2) (Kumar, 2000).

### 1.7 Cyclooxygenase and Lipoxygenase Metabolites

Once liberated, cyclooxygenase and lipoxygenase enzymes convert fatty acids to metabolically active lipids. The type and activity of the products depends upon the substrate: arachidonate (n-6) yields highly reactive dienoic prostaglandins and series 4 leukotrienes; n-3 fatty acids yield the far less active trienoic prostaglandins and series 5 leukotrienes (Calder, 2004; Prescott, 2005). Because arachidonic (AA) acid (n-6) usually predominates in plasma and membranes, dramatic elevations in dienoic products, e.g. thromboxane A<sub>2</sub> (TxA<sub>2</sub>), prostaglandin D<sub>2</sub> (PGD<sub>2</sub>) and E<sub>2</sub> (PGE<sub>2</sub>), occur in human plasma, urine, and bronchoalveolar lavage (BAL) fluid during ALI/ARDS (Lelcuk, 1984). Arguably TxA<sub>2</sub> is most consequential in ALI/ARDS by causing platelet aggregation, vasoconstriction and bronchoconstriction (Lelcuk, 1984). Evidence supporting the role of these mediators comes from experiments showing that administration of n-6 precursors increases TxA<sub>2</sub> production and worsens physiology (Palombo, 1999) and cyclooxygenase inhibitors (e.g. ibuprofen) and TxA<sub>2</sub> inhibitors (e.g. ketoconazole) or receptor blockers improve gas exchange, oxygen consumption, and airway and vascular resistance (Bernard, 1997; The Acute Respiratory Distress Syndrome Network, 2000).

Similarly, increases in 5-lipoxygenase metabolites of AA (e.g. leukotriene B<sub>4</sub>, C<sub>4</sub>, D<sub>4</sub>) have been demonstrated in ALI/ARDS (Bernard, 1991). Among these compounds LTB<sub>4</sub> is most significant because of its potent neutrophil and macrophage chemoattractant properties and ability to increase vascular permeability and respiratory burst. Experimentally LTB<sub>4</sub> infusion



has been associated with lung dysfunction, and antagonists of leukotriene production or receptor binding improve physiology in animal models of ALI/ARDS (Miller, R.F., 1992). Human clinical trials of leukotriene antagonists in ALI/ARDS have not been conducted.

Within hours of treating leukocytes *ex vivo* with EPA or DHA fatty acid composition and cell responses to stimuli are modified. *In vivo*, modest n-3 doses alter plasma and cellular content within 1-3 days (Chilton, F.H., 1993). Because of conformational differences, n-3 substrates have a 5-10 fold lower efficiency of conversion by desaturase enzymes than n-6 compounds (Simopoulos, 2000). Thus, when supplied in excess, n-3 fatty acids are competitive substrates decreasing total lipid mediator production. Moreover, the mediators formed from EPA (e.g. TxA<sub>3</sub> and LTB<sub>5</sub>) are less active than those derived from AA. For example, TxA<sub>3</sub> is at least 10 fold less potent than TxA<sub>2</sub> and LTB<sub>5</sub> is significantly less active than LTB<sub>4</sub> (Palombo, 1996). Likewise, administration of n-3 fatty acids in animals and humans is proven to decrease and alter the leukotrienes produced (Kumar, 2000).

EPA has another potential benefit by inhibiting the conversion of dihomogammalinolenic acid to arachidonic acid via the  $\Delta 5$  desaturase enzyme thus shunting eicosanoid production from TxA<sub>2</sub>, PGD<sub>2</sub> and PGE<sub>2</sub> to PGE<sub>1</sub> a compound with anti-aggregatory and vasodilatory properties (Fieren, 1992). Changes in lipid mediator production and profiles following n-3 fatty acid therapy have been associated with improved physiological measures in numerous animal and human studies suggesting therapeutic potential (Breil, 1996; Gadek, 1999; Lee, 1985).

### **1.8 Omega-3 Fatty Acids and Cytokine Mediators**

Neutrophilic inflammation is a pathologic hallmark of ALI/ARDS and strong evidence supports the roles of specific cytokines in this complex process. Very simplistically, LTB<sub>4</sub> and IL-8 attract and TNF and IL-1 promote adhesion and activation of neutrophils. Simultaneously TNF and IL-1 activate macrophages. Aggregates of activated neutrophils and alveolar macrophages release oxidants that subsequently damage membrane polyunsaturated fatty acids, further increasing alveolar-capillary permeability and disrupting epithelial barrier function. Reciprocally oxygen free radicals enhance TNF and other cytokine production. In addition to oxidant generation, TNF and IL-1 initiate pro-coagulant tissue factor activity on cell surfaces (Taylor, F.B., Jr., 1996). TNF and interleukins 1, 6 and 8 have been found in high concentrations in lung lavage fluid in ALI/ARDS victims (Donnelly, 1993; Donnelly, 1996) and persistent elevations, especially of IL-8 predict a poor prognosis (Miller, E.J., 1992). Because it is evanescent in plasma, TNF is uncommonly detected, and when present is seen at low levels. Instead, plasma IL-6 serves as a useful long-lived TNF surrogate. Although present at much lower levels than in BAL, plasma IL-8 can be detected and correlates with a poor outcome (Miller, E.J., 1992). Additional evidence suggests IL-10, a potent anti-inflammatory cytokine, exerts beneficial effects by down regulating TNF, IL-1, IL-6 and IL-8 production and increasing release of IL-1 soluble receptor (Chollet-Martin, 1994). Additional evidence supporting the beneficial role of IL-10 comes from the observation that low levels of IL-10 in BAL are associated with worse outcomes (Arndt, 2001).

Although pro-inflammatory cytokines are present in significant levels and correlate inversely with outcome, so far attempts to individually neutralize the effects of TNF or IL-1 using specific antagonists have not dramatically altered the course of human ALI/ARDS (Arndt, 2001).

Whether the failures reflect inefficiency of the antagonists tested, are indicative of the redundancy of inflammatory mechanisms, or are explained by the failure to adequately address the coagulopathic disease component is uncertain. Nevertheless, a simply administered, inexpensive, non-toxic therapy to decrease IL-1, IL-6, and IL-8 production while preserving IL-10 production remains an attractive notion for ALI/ARDS therapy.

Treatment of normal humans and ALI/ARDS patients with n-3 fatty acids dramatically decreases *ex vivo* production of TNF and IL-1 from stimulated mononuclear cells (Endres, 1989). In animal models of sepsis and ALI/ARDS, n-3 fatty acids significantly decrease inflammatory cytokine levels in plasma and lavage fluid and are associated with improved physiological parameters (Murray, 1995). In contrast to the suppression of pro-inflammatory cytokines seen following treatment with n-3 fatty acids, IL-10 levels are not suppressed suggesting n-3 fatty acids do not non-specifically down-regulate all cytokines. The mechanism(s) by which n-3 fatty acids inhibit cytokine activity are unknown. Hypotheses include: preserved or augmented IL-10 production (Donnelly, 1996); diversion of dihomogammalinolenic acid from AA production to E1 series prostaglandins discussed above; and altered nuclear kappa factor B activity mediated through changes in PPAR alpha and gamma activity (Schwartz, 1996; Sethi, 2002). In addition to the benefits of n-3 fatty acids in decreasing production of chemokines and lipid mediators, in higher doses they also decrease production and release of toxic oxidants.

Despite the convincingly beneficial results of n-3 fatty acids in experimental animals and *ex vivo* simulation studies of human leukocytes, their ability to reduce plasma or BAL pro-inflammatory cytokine levels in human ALI/ARDS remains largely un-investigated.

### **1.9 Human Clinical Studies of Omega-3 Fatty Acids in Inflammatory Disease**

Biochemical changes in lipid mediators, cytokines and coagulation proteins induced by n-3 fatty acid therapy outlined above are associated with physiological improvements in chronic neutrophilic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease (Cleland, 2003; MacLean, 2005; Romano, 2005; Simopoulos, 2002). Interestingly, chronic neurologic diseases with cognitive impairment have also been demonstrated to benefit from n-3 fatty acid therapy (Fenton, 2001; Terano, 1999). Benefits of n-3 fatty acid therapy have extended to *chronic* neutrophilic inflammatory lung diseases, such as chronic obstructive pulmonary disease (Matsuyama, 2005; Romieu, 2001) and cystic fibrosis (Freedman, 2004; Panchaud, 2005).

Two studies have demonstrated benefit of n-3 fatty acid supplementation in patients with severe sepsis or septic shock (Pontes-Aruda, 2006; Galban, 2000). Both studies demonstrated a significant reduction in mortality using omega-3 fatty acids and anti-oxidants compared to standard enteral nutrition, although concern has been raised about an abnormally high mortality rate in the control arm of the most recent study. Further, Galban and colleagues demonstrated fewer infectious complications with omega-3 fatty acid supplementation (Pontes-Aruda, 2006; Galban, 2000), while Pontes-Aruda et al found improvements in oxidation, more ICU-free and ventilator-free days, and the development of fewer organ dysfunctions (Pontes-Aruda, 2006).

## **1.10 Human Studies of Omega 3 Fatty Acids in ALI/ARDS**

Similarly, two randomized, controlled phase II studies of the effects of fish oil have been conducted in ALI patients using Oxepa®, a commercial product containing among many components, n-3 fatty acids (Gadek, 1999; Singer, 2006). Both studies suggest that Oxepa® is beneficial, but their results are not entirely similar, neither has been regarded as definitive, and the first trial published in 1999 has not changed clinical practice on a large scale. Of the hospitals involved in ARDSnet, only two use Oxepa® in their patients with ARDS. The two studies are summarized here.

The first trial (Gadek, 1999) included 148 patients with ALI randomized to Oxepa® or Pulmocare®. Treatment with Oxepa® changed plasma fatty acid profiles and decreased the total number of cells and neutrophils found in lung lavage fluid as early as day 4 of therapy. In addition, subsequent analysis of BAL fluid demonstrated a reduction in IL-8 and LTB<sub>4</sub> levels in patients fed the study formula (Pacht, 2003). Patients treated with Oxepa® also demonstrated significantly improved oxygenation, shorter ICU length of stay and duration of mechanical ventilation, and development of fewer new organ failures. Hospital mortality was also reduced in patients treated with Oxepa®, although not statistically significant (p=0.165). Interestingly, however, mortality in this study was much lower than expected in an era before lung protective ventilation (25% in the “control” patients receiving Pulmocare® and 16% in the Oxepa® patients), suggesting that these results may not be generalizable to all ALI patients. Further, only two-thirds of randomized patients were deemed evaluable and included in the analysis, dramatically limiting interpretation of the results (Gadek, 1999).

The second trial recently published (Singer, 2006) includes 100 patients, again randomized to Oxepa® or Pulmocare®. Physiologic variables including lung compliance and oxygenation were improved in the Oxepa® group. However, there was no difference in ICU length of stay or overall duration of mechanical ventilation, although the point estimates are similar to the Gadek trial, suggesting it was underpowered. Additionally, hospital mortality was not different and was very high, 75% in each group, again suggesting that the results are not generalizable. A second limitation is that the test article in both studies not only contained n-3 fatty acids, but also large amounts of gamma-linolenic acid (GLA), and other putative anti-oxidant compounds making attribution of the effect to omega-3 fatty acids difficult.

These preliminary data suggesting an improvement in outcomes are stronger for this nutraceutical intervention than for any other proposed study in ALI. Although the phase II data are suggestive, these two studies have significant limitations. Therefore, a large phase III trial as we have designed powered for clinically important endpoints is necessary to reproduce and confirm the prior results in a generalizable ALI patient population; such a study has the potential to change practice substantially.

## **1.11 Gamma-Linolenic Acid and Omega Three Fatty Acids**

Gamma-Linolenic acid (GLA) is an 18-carbon n-6 polyunsaturated fatty acid present in borage oil, flax seed oil, and evening primrose oil. The body normally produces GLA from the n-6 essential fatty acid, linoleic acid. However, certain conditions, including highly inflammatory

states, inhibit the action of the  $\Delta$ -6 desaturase enzyme, impairing the body's ability to convert linoleic acid to GLA. This renders GLA a conditionally essential fatty acid. As very little GLA is found in the diet, supplementation may be required. Several prior studies have shown that GLA supplementation reduced the signs and symptoms of chronic inflammatory diseases such as rheumatoid arthritis and atopic dermatitis (Leventhal, 1993; Morse, 1989; Tate, 1989). Until recently, these clinical effects seemed to be inconsistent with its biosynthesis, since GLA is a potential precursor of AA, a highly proinflammatory eicosanoid precursor. Recent studies, however, have found that human neutrophils contain the elongase that metabolizes GLA to dihomo- $\gamma$ -linolenic acid (DGLA) but not the  $\Delta$ -5-desaturase that converts DGLA to AA (Chilton, Lopez, 1996). Therefore, it appears that GLA supplementation to neutrophils leads to the accumulation of DGLA and not AA intracellularly. However, in vivo GLA supplementation can increase serum AA in humans, thus raising the potential for an increase in proinflammatory mediators (Johnson, 1997).

Moreover, EPA is an inhibitor of human  $\Delta$ -5-desaturase. In vitro and in vivo studies of GLA and EPA supplementation have found that the combination reduced serum and neutrophil leukotriene concentrations but did not increase serum AA concentrations (Barham, 2000; Johnson, 1997). It is important to note, however, that none of these human studies were performed in critically ill patients.

### **1.12 Summary of Omega-3 Fatty Acids and ALI / ARDS**

*Ex vivo* and *in vivo* data from animals and humans indicate n-3 fatty acids inhibit inflammatory effects of relevant cytokines, cyclooxygenase, and lipoxygenase products. Treatment with n-3 fatty acids maintains or increases levels of the anti-inflammatory cytokine IL-10. Human data confirm safe, well-tolerated doses of n-3 fatty acids alter fatty acid levels within days resulting in anti-inflammatory and anti-thrombotic effects. Substantial data from chronic inflammatory human conditions other than ALI / ARDS (e.g. rheumatoid arthritis, inflammatory bowel disease) indicate n-3 fatty acids favorably alter clinical outcomes. The Phase II human study of n-3 fatty acids in ALI / ARDS noted above offers strong support for the concept. We hypothesize that increasing the ratio of n-3 fatty acids in patients with ALI / ARDS will acutely alter the lipid composition of plasma and cell membranes, decrease the levels of pro-inflammatory cytokines, and decrease cyclooxygenase and lipoxygenase products. Altering these inflammatory mechanisms will favorably impact the important clinical endpoints of mortality, ventilator free days, and organ failure free days.

### **1.13 Oxidative Stress and ARDS**

Oxidative stress is elevated with many disease states (Cracowski, 2000; Montuschi, 2000; Wood, 2000), and it is reasonable to postulate that levels of oxidative stress are even higher in illnesses representing more severe perturbations of the disease spectrum. In many critical illnesses, especially ones emanating from infection, macrophages are increased, recruited, and activated. The resultant increase in macrophage oxidative burst is vital in helping to overcome the inflammatory process. In addition, energy expenditure increases in critical illness. Studies have demonstrated that patients with sepsis and septic shock demonstrate elevated levels of oxidant stress (Goode, 1995; Gutteridge, 1999). Furthermore, the acute respiratory distress syndrome, a predominantly neutrophilic inflammatory process, also results in increased levels of oxidative

stress (Carpenter, 1998; Gutteridge, 1999; Schmidt, 2004). Some studies have suggested that levels of oxidative stress, as demonstrated by lipid peroxidation, correlate with worse outcomes in critically ill patients (Cowley, 1996). Studies of anti-oxidant therapy independently in patients with ARDS, however, are limited to trials investigating N-acetylcysteine (NAC). Despite demonstrating improved pulmonary physiology, three moderate-sized clinical trials investigating intravenous NAC failed to demonstrate any benefit in clinical outcomes, including no difference in 30-day or 60-day mortality, ventilator-free days, or ICU-free days (Bernard, 1997; Jepsen, 1992; Suter, 1994). Unfortunately, none of the studies measured changes in markers of oxidative stress. One study combining omega-3 fatty acid and anti-oxidant treatment, however, found normalization of low anti-oxidant levels, but no alteration in measures of oxidative stress (Bernard, 1997; Jepsen, 1992; Nelson, 2003; Suter, 1994).

#### **1.14 Caloric Restriction, Energy Expenditure, and Oxidative Stress**

Trophic feedings, as utilized in this proposal, provide an enteral feeding regimen low in calories compared to full-calorie feedings. Caloric restriction (Koubova, 2003) delays the development of a wide spectrum of diseases, including kidney disease, neoplasias, diabetes, and autoimmune diseases, resulting in prolonged survival in multiple species (Fernandes, 1976; Jolly, 2005; Lane, 2001; Sohal, 1996). Although the mechanism of its action remains unknown it has been proposed that caloric restriction reduces oxidative damage generated by ROS produced during respiration (Afanas'ev, 2005; Heilbronn, 2006). Normally about 3% of oxygen consumed is converted to ROS by mitochondria; hence as energy expenditure increases, the ROS burden increases. Likewise, reducing energy expenditure decreases formation of radical generating molecules. Caloric restriction effectively decreases energy expenditure (Heilbronn, 2006), and has been shown to decrease the production of ROS, resulting in less oxidative stress in animal models (Yu, 2005).

#### **1.15 Nutrition and Oxidative Stress**

Whereas antioxidants, when given as nutritional supplements, reduce oxidative stress (Dietrich, 2002; Nathens, 2002), the effect of feeding on these processes remains unknown, especially in critically ill patients. Polyunsaturated fats (PUFA), which make up the bulk of fats in standard tube feed formulas, are excellent substrates for lipid peroxidation (Napolitano, 2004). With rare exception (Stier, 2001), *in vitro* studies suggest that oxidative susceptibility increases with polyunsaturated fats (Cosgrove, 1987) and studies in non-critically ill patients have demonstrated similar increases in lipid peroxidation with PUFA intake (Abbey, 1993; Van Gossum, 1988). In addition providing differing amounts of fatty acids demonstrates increased oxidative stress in patients given additional PUFAs (Abbey, 1993; Van Gossum, 1988). Omega-3 fatty acid supplementation alters the lipid composition of plasma membranes, resulting in less arachidonic acid available for peroxidation. However, the effect of omega-3 fatty acid supplementation on levels of *in vivo* oxidative stress is unknown. In addition, since inflammation increases oxidative stress, decreasing inflammation either through administration of omega-3 fatty acids or trophic feeds, may also result in lower levels of oxidative stress.

#### **1.16 Summary of Anti-oxidants and ALI / ARDS**

Critically ill patients have increased levels of oxidative stress. We hypothesize that anti-oxidant supplementation, in the form of Vitamin C and Vitamin E, will scavenge free radicals and reduce

oxidative stress in patients with ALI / ARDS. In addition, we hypothesize that omega-3 fatty acid supplementation will complement the anti-oxidant effect by reducing the availability of arachidonic acid, a major substrate for lipid peroxidation and that caloric restriction in the form of trophic feeds will further reduce oxidative stress by decreasing energy expenditure. Finally, both omega-3 fatty acid supplementation and trophic enteral feedings have the potential to indirectly attenuate oxidative stress by reducing inflammation. Decreasing oxidative stress by any or all of these methods will favorably impact the important clinical endpoints of mortality, ventilator free days, and organ failure free days.

### **1.17 Measurement of Long Term Outcomes and Acute Lung Injury**

Emerging data indicate that survivors of acute lung injury have substantial disability after recovery from acute lung injury. After hospital discharge, only about one-third return to home and more than one-half reside in skilled nursing facilities or rehabilitation facilities (Rubenfeld, 2005). Up to one year later, most patients have serious deficits in health-related quality of life, functional performance, cognition, and employment (Herridge, 2003; Hopkins, 2005). Mortality and ventilator-free days, which have been the primary outcomes in most clinical trials of treatments for acute lung injury, do not capture these important longer-term decrements (Brower, 2004; Schoenfeld, 2002; The Acute Respiratory Distress Syndrome Network, 2000). Moreover, it has recently become clear that acute lung injury, contrary to previous belief, becomes a chronic, disabling pulmonary condition in many cases (Herridge, 2003). To capture the full impact of any treatment for acute lung injury, longer term outcomes must be assessed.

The effects of treatment for acute lung injury on short term mortality may not capture the full impact of treatment over the longer term. A treatment may have early benefit that is maintained, amplified, or attenuated over a longer time period. For example, an invasive strategy for diagnosing ventilator-associated pneumonia reduced 14 day mortality, but the benefit decreased thereafter and the mortality benefit was lost (Fagon, 2000). In addition, a treatment may improve mortality but have additional deleterious effects that adversely affect long term outcomes such as health-related quality of life and functional performance. For example, parenteral corticosteroids, which may have some immediate benefit in late-phase ARDS, may have detrimental longer-term effects on muscle function and weakness that lead to impaired physical functioning (Herridge, 2003; Steinberg, 2006). To fully evaluate new therapies for acute lung injury, a broad spectrum of long term outcomes must be ascertained. Moreover, measurement of long-term outcomes is necessary to compare the cost-effectiveness of different strategies for ARDS (Angus, 2001).

## **2 Objectives**

### **2.1 Primary Objectives**

- Evaluate the efficacy and safety of initial trophic enteral feeds followed by advancement to full-calorie enteral feeding vs. initial advancement to full-calorie enteral feeding management strategies on mortality, ventilator-free days, ICU-free days, and organ failure in patients with Acute Lung Injury or Acute Respiratory Distress Syndrome

- Evaluate the safety and efficacy of omega-3 fatty acid, gamma-linolenic acid (GLA), and anti-oxidant supplementation on mortality, ventilator-free days, ICU-free days, and organ failure in patients with ALI or ARDS

## **2.2 Secondary Objectives**

To develop and analyze a clinical database of patients enrolled in the clinical trial who are well characterized and followed for 12 months for the purpose of answering questions about the natural history of ARDS and evaluating the effect of different interventions and patterns of supportive care.

## **2.3 Primary Hypotheses**

- Initial trophic feeding followed by full-calorie enteral feeding will increase the number of ventilator-free days to study day 28 in patients with ALI or ARDS by reducing systemic inflammation and the number of feeding complications as compared to early, full-calorie enteral feeding.
- Omega-3 Fatty Acid, GLA, and anti-oxidant supplementation, as compared to placebo, will increase the number of ventilator-free days to study day 28 in patients with ALI or ARDS by attenuating systemic inflammation.

## **2.4 Secondary Hypotheses**

- Initial trophic feeding will have anti-inflammatory effects demonstrated by decreased plasma IL-6 and IL-8 levels in patients with ALI or ARDS compared to early, full-calorie enteral feeding.
- Initial trophic feeding followed by full-calorie enteral feeding will decrease the incidence of gastrointestinal intolerances (vomiting, aspiration, regurgitation, diarrhea, elevated gastric residual volumes, and abdominal distention and cramping) compared to early, full-calorie enteral feeding.
- Initial trophic feeding followed by full-calorie enteral feeding will decrease the incidence of ventilator-associated pneumonia in patients with ALI or ARDS compared to early, full-calorie enteral feeding.
- Initial trophic feeding followed by full-calorie enteral feeding will decrease the incidence of developing bacteremia in patients with ALI or ARDS compared to early, full-calorie enteral feeding.
- Omega-3 fatty acid supplementation, as compared to placebo, will selectively increase plasma levels of EPA and DHA, resulting in an increased omega-3 to omega-6 fatty acid ratio in plasma.
- Omega-3 fatty acid, GLA, and anti-oxidant supplementation, as compared to placebo, will decrease the plasma levels of pro-inflammatory cytokines IL-6 and IL-8.

- Omega-3 fatty acid and anti-oxidant supplementation will reduce the urinary ratios of stable metabolites of leukotriene B<sub>4</sub> to B<sub>5</sub> indicating alterations in lipid utilization by lipoxygenase enzymes among ALI/ARDS patients compared to placebo.
- Anti-oxidant supplementation will reduce the systemic oxidative stress as measured by urinary F<sub>2</sub>-isoprostane metabolites (Morrow, 1999) among ALI/ARDS patients compared to placebo.

### 3 End Points

Analysis of primary and all secondary endpoints will be conducted on an intention to treat basis. A secondary analysis will be performed looking at patients who achieved greater than 70% of full-calorie feeds for the initial 6 days.

#### 3.1 Primary Endpoint

1. Ventilator-Free Days to study day 28

VFDs is a composite endpoint that is affected by mortality and duration of mechanical ventilation in survivors (Schoenfeld, 2002), which has been chosen as the primary endpoint for a number of reasons. Preliminary data suggests that omega-3 fatty acid and anti-oxidant supplementation decreases inflammation in the lungs in patients with ALI. VFDs provide a validated measure of improved lung function, even if overall mortality is only minimally altered. In addition to also possibly altering inflammation, full-calorie feedings may place patients at risk for aspiration, which may result in increased mortality, but will result in fewer ventilator-free days, even in non-fatal cases. Further, VFDs is a measure of a morbidity outcome and it is directly related to “days of assisted ventilation.” However, a trend in one treatment group toward early patient death would likely decrease the number of days of assisted ventilation. This example of decreased days of assisted ventilation is misleading as the treatment group actually had a worse outcome. Measuring ventilator days in survivors would offset the problem of early mortality decreasing ventilator days. However, if a treatment group had a favorable trend towards improved survival, but required additional ventilator days for survival, “average number of ventilator days in survivors” could also be misleading. VFDs represent a measurable outcome that is favorably affected by both shorter duration of assisted ventilation in survivors and lower mortality.

VFD to day 28 is defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and remains free of assisted breathing to day 28. If a patient returns to assisted breathing and subsequently achieves unassisted breathing to day 28, VFD will be counted from the end of the last period of assisted breathing to day 28 unless a period of assisted breathing was less than 24 hours and the purpose of assisted breathing was a surgical procedure. If a patient was receiving assisted breathing at day 27 or dies prior to day 28, VFD will be zero. Patients transferred to another hospital or other health care facility prior to day 28 while still receiving assisted breathing will be followed to assess this efficacy measure. Unassisted breathing is defined as breathing with facemask or nasal prong oxygen (or room air)



following extubation, T-tube breathing, breathing with continuous positive airway pressure (CPAP  $\leq 5$  cm H<sub>2</sub>O without PS or IMV assistance), or tracheotomy mask breathing.

### 3.2 Secondary Endpoints

1. The secondary efficacy variable for the trial is mortality prior to hospital discharge with unassisted breathing. Patients alive in hospital at day 60 will be considered to have survived.
2. Mortality before hospital discharge home, with unassisted breathing, to day 90. Patients alive in hospital to day 90 will be considered to have survived.
3. Number of ICU-free days at 28 days after randomization.
4. Number of organ failure-free days at 28 days after randomization. Organ failure will be defined by previously validated definitions for renal, circulation, central nervous system, hematologic, and hepatic organ and system failures (Bernard, 1997).

Organ failure is defined as present on any date when the most abnormal vital signs or clinically available lab value meets the definition of clinically significant organ failure according to the Brussels Organ Failure Table. Patients will be followed for development of organ failures to death, hospital discharge or study day 28, whichever comes first. Each day a patient is alive and free of a given clinically significant organ failure will be scored as a failure-free day. Any day that a patient is alive and free of all 5 organ failures will represent days alive and free of all organ failure. Central nervous system dysfunction is evaluated using the Glasgow Coma Scale.

5. Number of days between the day of first meeting criteria for weaning-readiness (see Appendix G, section G.2.) and day 28 after randomization.
6. Mortality and VFDs in patients with pre-randomization PaO<sub>2</sub>/F<sub>I</sub>O<sub>2</sub>  $\leq 200$ .
7. Change in plasma levels of IL-6, IL-8, VWF, SPD, and total protein concentrations from baseline to study day 3.
8. Ventilator free days and mortality prior to hospital discharge with unassisted breathing to day 60 and number of ventilator-free days to day 28 in patients with shock (defined in 2.1.2) at the time of randomization.

### 3.3 Other Endpoints

Many of these proposed outcomes are not meant to definitively establish the underlying mechanisms, but instead will explore biochemical endpoints to provide additional support or generate other hypotheses of how the interventions may result in different clinical outcomes.

1. Reduction of PaO<sub>2</sub> / FiO<sub>2</sub> ratio on study days 1-7
2. Improvement in Lung Injury Score on study days 1-7
3. Number of gastrointestinal intolerances (aspiration, vomiting, regurgitation, diarrhea, elevated gastric residual volumes, abdominal distention and cramping) on study days 1-7
4. Level of systemic inflammation, as measured by plasma IL-6 and IL-8 levels.
5. Degree of lipid utilization by lipoxygenase, as measured by the ratio of stable urinary metabolites of leukotriene B<sub>4</sub> to B<sub>5</sub>.
6. Measure of oxidative stress on days 3, 6 and 12 compared to baseline as measured by urinary levels of F<sub>2</sub>-isoprostane metabolites

7. Incidence of bacteremia developing
8. Incidence of *Clostridium difficile* induced diarrhea.
9. Incidence of ventilator-associated pneumonia
10. Serum levels of markers of nutrition, including albumin and total protein levels between baseline and days 6 and 12.

*Clostridium difficile* diarrhea will be diagnosed by one or more daily stool specimen positive for cytotoxin assay or enzyme immunoassay. Patients with more than 3 liquid stools totaling more than an estimated 500 ml of stool per day, or those with systemic inflammatory response syndrome unexplained by other infection, may have up to three daily stool samples sent for *C. difficile* investigation (either cytotoxin assay or enzyme immunoassay).

Bacteremia will only be considered if it develops greater than 24 hours after the initiation of study procedures and is documented with a positive blood culture. The primary medical team, using clinical judgment, will determine when blood cultures are sent. Coagulase negative (or thermo nuclease negative) *Staphylococci* or *Corynebacterium* bacteremia require the isolation of these organisms from at least two blood cultures drawn within 24 hours of each other containing the same organism in order to be deemed significant.

Ventilator-associated pneumonia (VAP) is a difficult diagnosis to make with certainty, especially in patients with underlying ALI or ARDS. However, for the purposes of this trial, an objective definition of VAP will be used in order to standardize the reporting and reduce bias during the first 6 days of enteral feeding given the unblinded administration of enteral feeding volumes. As such, VAP will be defined using the same scoring system as the ARDS network used for the LaSRS study [redacted]. The scoring system incorporates temperature, leukocyte count, sputum or tracheal aspirate Gram stain and culture, and chest radiograph results. This score will be calculated as available as long as the patient remains ventilated. The certainty of VAP will be graded as either suspected or possible vs. probable using the criteria listed in Appendix A.

## **4 Study Population and Enrollment**

### **4.1 Number/Source/Screening**

The trial will accrue a maximum of 1000 patients into a 2 x 2 factorial study design (see diagram below) over a 3-4 year interval. Patients with ALI or ARDS will be recruited from intensive care units at NIH ARDS Network centers. Study coordinators will visit intensive care units daily to identify potential candidates for enrollment (see inclusion criteria, section 4.2, and exclusion criteria, section 4.3). Permission to approach patients and/or their families will be requested from the attending physicians. All patients meeting the inclusion criteria will be entered on a screening log. If the patient is not enrolled, the screening log will include information explaining why enrollment did not occur (exclusion criteria, attending physician denial, patient refusal, etc. see Appendix L).

## 2 X 2 Factorial Study Design

	Unblinded	<b>Trophic</b>	<b>Full-calorie</b>
	Blinded	(10 cc / hr X 144 hrs)	(within 24 hr)
<b>Study Solution</b> (21 days or UAB)		n = 250	n = 250
<b>Placebo</b>		n = 250	n = 250

### 4.2 Inclusion Criteria

Patients will be eligible for inclusion if they meet all of the below criteria. Criteria 1-3 must all be present within a 24-hour time period:

Acute onset (defined below) of:

1.  $PaO_2 / FiO_2 \leq 300$  (intubated). If altitude > 1000m, then  $PaO_2 / FiO_2 \leq 300 \times (PB/760)$
2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph. The infiltrates may be patchy, diffuse, homogeneous, or asymmetric
3. Requirement for positive pressure ventilation via endotracheal tube, and
4. No clinical evidence of left -sided cardiac failure to account for bilateral pulmonary infiltrates.
5. Intention of primary medical team to enterally feed the patient

The 48-hour enrollment time window begins when criteria 1-3 are met. If a patient meets the first three inclusion criteria but has a PAOP (Pulmonary Arterial Wedge Pressure) greater than 18 mmHg, then the first four criteria must persist for more than 12 hours after the PAOP has declined to  $\leq 18$  mmHg, and still be within the 48-hour enrollment window.

“Acute onset” is defined as follows: the duration of the hypoxemia criterion (#1) and the chest radiograph criterion (#2) must be  $\leq 28$  days at the time of randomization. Opacities considered “consistent with pulmonary edema” include any opacities not fully explained by mass, atelectasis, or effusion or opacities known to be chronic (greater than 28 days). Vascular redistribution, indistinct vessels, and indistinct heart borders alone are not considered “consistent with pulmonary edema” and thus would not count as qualifying opacities for this study.

### 4.3 Exclusion Criteria

1. Age younger than 13 years.
2. Greater than 48 hours all since inclusion criteria met

3. Neuromuscular disease that impairs ability to ventilate with out assistance, such as cervical spinal cord injury at level C5 or higher, amyotrophic lateral sclerosis, Guillain-Barré Syndrome, or myasthenia gravis (See Appendix B)
4. Pregnant or breast-feeding
5. Severe chronic respiratory disease (See Appendix B for detailed exclusion criteria).
6. Burns greater than 40% total body surface area
7. Malignancy or other irreversible disease or condition for which 6-month mortality is estimated to be greater than 50% (See Appendix B).
8. Allogeneic bone marrow transplant within the last 5 years
9. Patient, surrogate, or physician not committed to full support (Exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest).
10. Severe chronic liver disease (Child-Pugh Score of 11-15)
11. Diffuse alveolar hemorrhage from vasculitis.
12. Morbid obesity (> 1kg/cm body weight)
13. No consent/inability to obtain consent
14. Unwillingness or inability to utilize the ARDS network 6 ml / kg PBW ventilation protocol
15. Moribund patient not expected to survive 24 hours
16. No intent to obtain central venous access for monitoring intravascular pressures.
17. > 72 hours since mechanical ventilation initiated
18. Refractory shock (See Appendix B)
19. Unable to obtain enteral access
20. Presence of partial or complete mechanical bowel obstruction, or ischemia, or infarction
21. Current TPN use or intent to use TPN within 7 days
22. Severe malnutrition with BMI < 18.5 or loss of > 30% total body weight in the previous 6 months
23. Laparotomy expected within 7 days
24. Unable to raise head of bed 30-45 degrees
25. Short-bowel syndrome or absence of gastrointestinal tract
26. Presence of high-output (> 500 cc/day) enterocutaneous fistula
27. INR > 5.0 or platelet count < 30,000 / mm<sup>3</sup> or history of bleeding disorder
28. Intracranial hemorrhage within the previous month
29. Allergy to enteral formula, n-3 fatty acids, gamma-linolenic acid, vitamin E, vitamin C, beta-carotene, taurine, or L-carnitine
30. Requirement for, or physician insistence on, enteral formula supplemented with omega-3 fatty acids (ex: Oxepa®, Impact®) or providing omega-3 fatty acid, GLA, or anti-oxidant supplementation

#### **4.4 Enrollment, Randomization, and Study Initiation Time Window**

All patients must be randomized within 48 hours of meeting inclusion criteria for ALI (inclusion criteria 1-3) and within 72 hours of initiating mechanical ventilation. The window for randomization will begin at the time of meeting all inclusion criteria and/or the time of documentation of mechanical ventilation, regardless of hospital location. The first three inclusion criteria may be met at either the Network or referring hospital. Following

randomization, the low tidal volume protocol for mechanical ventilation must be initiated within one hour (if not already being utilized). Enteral feeds and the enteral feeding protocol must be initiated within 6 hours of randomization. The first dose of study emulsion or placebo must be administered within 6 hours of randomization.

#### **4.5 Informed Consent**

Informed consent will be obtained from each patient or surrogate prior to enrollment in the trial. No study procedures will be done prior to obtaining informed consent.

#### **4.6 Randomization**

After obtaining a signed and dated informed consent, the coordinating center will be called and an assignment, in the form of a study ID number, will be made by computer-generated randomization to OMEGA or placebo and early versus late trophic feedings.

Randomization will be accomplished with a web based randomization system. Each research coordinator will have a unique Personal Identification Number (PIN). The randomization will provide a patient ID number to the pharmacy that will dispense either active treatment, or placebo based on a predetermined list in the research pharmacy. The pharmacist will be unblinded to the treatment assignments. He or she will be responsible for treatment assignments, formulations, and maintaining the list of codes revealing which treatment is being taken by each study participant. In addition the study personnel will be informed if the patient is to receive trophic or full feedings.

The randomization will be stratified by institution, and by shock at study entry to one of the four nutrition study combinations.

#### **4.7 Minorities and Women and Children**

Gender and racial patient subsets were considered by the NHLBI in selecting the Network Centers. The demographic profiles of the Centers selected for the Network show that the aggregate patient population contains representative proportions of minorities and women. Recruitment of minorities and women will be monitored by the Network Coordinating Center. If necessary, additional recruitment efforts will be made at specific centers to ensure that the aggregate patient sample contains appropriate gender and minority subsets.

Children will be enrolled who are 13 years and older. There is general agreement that children in this age range have pathophysiology and outcomes similar to adults with ALI. In addition the study procedures called for in the protocol can be readily carried out safely and effectively in this population.

It is less clear that this is so for children under the age of 13. A joint committee of the ARDSnet and Pediatric ALI investigators (PALISI) is actively debating this issue. Once their report has been reviewed and accepted by the ARDSnet Steering Committee, it will be forwarded to the DSMB with or without proposed changes in the trial depending on the recommendations presented.

## 5 Study Procedures

### 5.1 Enteral Feeding Procedures

#### 5.1.1 Enteral Feeding Formula

Feedings in both groups will employ a sterile, commercially available standard enteral formula (not supplemented with n-3 fatty acids) used in the ICU. Any formula that does not contain supplemental n-3 fatty acids or anti-oxidants will be acceptable to use. Enteral formulas supplemented with n-3 fatty acids will not be allowed to be utilized due to the confounding effects of the n-3 fatty acids. Neither n-3 fatty acid, nor anti-oxidant supplementation will be permitted during the study. The list of formulas that are not allowed includes: Oxepa®, Impact®, Peptamen AF®, Crucial®, Optimental® and Pivot 1.5®.

#### 5.1.2 Enteral Feeding Site

The location and type of enteral feeding tube (nasogastric, nasoenteric, PEG, orogastric, oroenteric, etc.) will not be randomized, but will instead be determined by the patient's primary medical team. The location of the feeding will be documented on the case report form. Consideration should be made for advancing the feeding tube to a post-pyloric position in patients receiving gastric feeds who experience multiple elevated gastric residual volumes (see section 5.1.4) or vomiting (see section 5.1.7.4).

#### 5.1.3 Enteral Feeding Rates

All patients will have enteral feeds started within 6 hours of being enrolled and randomized. Upon admission to the ICU, a full-calorie feeding rate should be determined. The full-calorie feeding rate will be calculated to deliver 25-35 kcal/kg PBW each day (Cerra, 1997). If a formal dietary evaluation is done, the dietary recommendation can be used as an acceptable alternative full-calorie rate.

The following formulas will be utilized to calculate predicted body weight (PBW):

For males:  $PBW \text{ (kg)} = 50 + 2.3 [\text{height (inches)} - 60] = 50 + .91 (\text{height (cm)} - 152.4)$

For females:  $PBW \text{ (kg)} = 45.5 + 2.3 [\text{height (inches)} - 60] = 45.5 + .91 (\text{height (cm)} - 152.4)$

##### 5.1.3.1 Trophic Enteral Feeding Treatment Group (Trophic Feeding Group)

All patients randomized to trophic enteral feedings will have enteral feeds started at 10 cc / hr and continued at this rate for 144 hours (see Trophic Feeding Protocol, Appendix C) provided gastric residuals remain at an acceptable level (see Gastric Residuals, section 5.1.4) and provided the patient remains on the ventilator. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates using the same protocol as for the full-calorie feeding treatment group (see section 5.1.3.2 and Appendix D) provided the patient remains on the ventilator.

































the study will be 90.7%. Changes in the number or spacing of the interim analyses will have a minor effect on the power. With this design, assuming that the pattern of deaths and extubations is similar to the FACTT fluid study, there is a 82% chance that the study will show both a significant effect of VFD and a nominally positive benefit in mortality.

The DSMB will be advised to consider mortality differences in deciding whether to stop the trial. For example, they might decline to stop the trial for efficacy if the mortality difference would make the positive benefit in ventilator free days difficult to interpret and they might decline to stop the trial for futility if there is a positive mortality benefit. For example, if there was no difference in vent free days but a trend towards a survival benefit the DSMB might continue past a futility boundary. The stopping rules have been set up so that this would not invalidate the trial if such judgments were made. The efficacy boundary has been developed without regard to the futility boundary. Thus if the futility boundary is crossed but the trial is not stopped the trial can still achieve a 0.025 one-sided significance level.

Table 2 shows the characteristics of this boundary if we had the interim reports described above. The second column is the nominal p-value to stop for efficacy; the third and fourth columns are the difference in VFD to stop for efficacy and futility. The next columns are the error spending functions. The type I error spending function is the probability that the upper boundary will be exceeded under the null hypothesis. The type II error spending function is the probability that the statistic will be below the lower boundary at an interim analysis or under the upper boundary at the final analysis under the alternative hypothesis. The probability of stopping for futility is given in the seventh column and the probability of stopping for efficacy in the eighth column. The final column shows the confidence interval for the difference in VFD if the trial stopped for efficacy at that look and the treatment effect just exceeded the stopping boundary.

**Table 2: Stopping Boundaries**

Number of patients	P-value Efficacy 2-sided	Difference Efficacy	Difference Futility	Type I Error Spending 1-sided	Type II Error Spending	Prob stop futility	Prob Stop efficacy	Confidence interval when no difference
100	1.5 E-6	9.5		7.6E-11	0	0	5E-8	9.3-17.6
250	5 E-5	3.8	-0.50	2.56 E-5	0.0128	0.30	0.009	2.8-8.0
500	0.0042	1.9	0.14	0.0021	0.0232	0.31	0.31	.8-4.5
750	0.0194	1.3	0.35	0.0104	0.0287	0.17	0.41	.3-3.2
1000	0.0429	0.95	0.46	0.0250	0.0923	0.09	0.18	0.0-2.6

## Secondary Endpoints

### Mortality

Mortality will be compared at interim data analyses using Kaplan Meier estimates at 60 days and their associated standard errors. This analysis will be stratified as above and a test for interaction of treatment with strata will be presented. At the end of the study sixty-day mortality will be compared using a Mantel-Haenzel test as long as all patients can be followed. If not the method used for the interim analyses will be used.

## Other Endpoints

The number of ICU-free days, Organ-Failure Free days, and days from first weaning readiness will be analyzed in the same manner as is described above for the primary endpoint. Subset analysis defined in the secondary analyses section will use an analysis of variance. First we will check for interactions and then, if significant, analysis will be performed for each of the specified subsets. In addition we will test for interactions between treatment and gender and race as per NIH guidelines (National Institutes of Health, 2001).

Changes in plasma levels of IL-6, IL-8, and protein will be compared in two analyses. An analysis of covariance will test for a treatment effect on the day 3 value of these variables using the day 0 value as a covariate. In addition, a multivariate analysis of variance will test for a baseline difference between day 3 and day 0.

Table 3 illustrates the detectable differences for endpoints, assuming 1000 patients enrolled, 90% power, and a two-sided alpha-level of 0.05.

**Table 3: Detectable Differences for Secondary Endpoints**

Variable	Incidence or Mean	Standard Deviation	Detectable Difference
PaO <sub>2</sub> / FiO <sub>2</sub>	155	73	15
ICU free days	13.4 days	12.6 days	2.6 days
Shock free days	19.1 days	4.93 days	2.23 days
Plasma IL-6 (pg/ml)	1252	862	177
Plasma IL-8 (pg/ml)	149	93	19
28 day hospital mortality	22%		8.2%
90 day hospital mortality	25.4%		8.6%

Changes in physiologic lung indices on days 1-7 will be compared using a multivariate analysis of variance.

## Phase 1 Pharmacokinetics

Plasma will be collected for measuring DHA, EPA and AA levels at days 0, 3, 6 and 12 from the first 30 patients receiving the placebo and the first 30 patients receiving the omega-3 fatty acid study emulsion. When the DSMB meets after approximately 100 patients have been enrolled, the DSMB will look at plasma EPA, DHA, and arachidonic acid and the ratio of omega-3 to omega-6 fatty acids in the blood on day 3 in these 60 patients to ensure that the omega-3 fatty acids are being absorbed. An estimate of the detectable difference is given in table 4 below, assuming 80% power and two-sided alpha level of 0.05. These estimates are conservative because they don't take into account the reduction of variance due to the use of the day zero value as a covariate.

**Table 4: Detectable Difference for Plasma Omega-3 Fatty Acids**

Variable	Incidence or Mean	Standard Deviation	Detectable Difference
Plasma EPA (% total)	0.645	0.2	0.15

lipid)			
Plasma DHA (% total lipid)	2.54	0.13	0.10
Plasma arachidonic acid (% total lipid)	9.8	0.38	0.28
EPA+DHA / AA ratio	0.32	0.1	0.07

Twice during the early part of the study, the DSMB will evaluate the glucose control between the trophic and full-calorie arms to ensure that the levels of blood glucose are not clinically different between the groups over the first 6 days of the study. These evaluations will occur after approximately 100 and 250 patients are enrolled in the study. Should the blood glucose values differ between the groups at these evaluations, the guidelines for controlling blood glucose levels for the remainder of the study will be adjusted in an attempt to equalize the blood glucose levels for the study.

## **8 Data Collection and Site Monitoring**

### **8.1 Data Collection**

The research coordinators will collect data and record it either on paper data sheets or in a custom-designed computer database. Data will be transferred to the Clinical Coordinating Center on a prescribed basis through a web-based data collection program.

### **8.2 Site Monitoring**

Site visits will be performed on a regular basis by the Data Coordinating Center, to ensure that all regulatory requirements are being met and to monitor the quality of the data collected. Records of Institutional Review Board approvals and patients' charts will be examined on a spot check basis to evaluate the accuracy of the data entered into the database.

## **9 Risk Assessment**

This study involves randomization of two separate (but potentially interacting) interventions: 1) Initial trophic enteral feeds followed by advancement to full-calorie enteral feeds vs. initial full-calorie enteral feeds, and 2) omega-3 fatty acid supplementation vs. placebo. Each of the two randomizations carries with it potential risks (and potential offsetting benefits), and the possible interactions between the two trials may also have risk or benefit.

### **9.1 Risks of Enteral Feedings**

Potential risks of enteral feedings exist in both feeding groups. Common risks of enteral feeding are abdominal distention, cramping, nausea, and diarrhea. Uncommon risks of enteral feeding include vomiting, aspiration, and intestinal ischemia.























## B Exclusion Definitions

### 1. Malignant and Irreversible Conditions

- a. Poorly controlled neoplasms (proven by surgery, computed tomographic scan, biopsy or other documented method)
- b. Known HIV positive with known end stage processes (e.g., progressive multifocal leukoencephalopathy, systemic mycobacterium avium infection) with known CD4 count < 50.
- c. Prior cardiac arrest requiring CPR without fully demonstrated neurologic recovery
- d. New York Heart Association Class IV subjects (defined as subjects who have cardiac disease resulting in inability to carry out physical activity without discomfort. Symptoms of cardiac insufficiency or of anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased).
- e. Chronic respiratory condition making patient respirator dependent.

### 2. Refractory Shock

Refractory shock is defined as the requirement of any of the following to obtain a blood pressure adequate for perfusion of tissues

- a. Dopamine infusion at rate  $\geq 15$  mcg / kg / min
- b. Dobutamine infusion at rate  $\geq 15$  mcg / kg / min
- c. Epinephrine or Norepinephrine infusion at rate  $\geq 30$  mcg / min
- d. Phenylephrine infusion at rate  $\geq 50$  mcg / min
- e. Milrinone infusion at rate  $\geq 0.5$  mcg / kg / min
- f. Vasopressin infusion at rate  $> 0.04$  U / min
- g. Intra-aortic Balloon Pump

### 3. Child-Pugh Score (Pugh, 1973)

Points	Class
5-6	A
7-9	B
$\geq 10$	C

Measurement	Numerical Score for Increasing Abnormality		
	1	2	3
Ascites	None	Present	Tense
Encephalopathy	None	Grade I or II	Grade III or IV
Bilirubin (mg/dl)	< 2	2-3	> 3
Albumin (g/L)	> 35	28-35	< 28
Prothrombin time (sec. prolonged)	1-4	4-10	> 10

#### **4. Neuromuscular Disease Impairing the Ability to Ventilate Spontaneously**


- a. Amyotrophic lateral sclerosis
- b. Guillain-Barré Syndrome
- c. Myasthenia gravis
- d. Upper spinal cord injury at level C5 or above
- e. Kyphoscoliosis or chest wall deformity resulting in severe exercise restriction (unable to climb stairs or perform household duties), secondary polycythemia, or respirator dependence

#### **5. Severe Chronic Respiratory Disease**


Any of the following is considered severe chronic respiratory disease and excludes a patient from being eligible for enrollment:

1. FEV<sub>1</sub> less than 20 ml/kg PBW (e.g. 1.4 L for a 70 kg person), or
2. FEV<sub>1</sub>/VC less than 50% predicted, or
3. Chronic hypercapnia (PaCO<sub>2</sub> greater than 45 mmHg) and/or chronic hypoxemia (PaO<sub>2</sub> less than 55 mmHg) on F<sub>1</sub>O<sub>2</sub> = 0.21, or
4. Radiographic x-ray evidence of any chronic over-inflation or chronic interstitial infiltration, or
5. Hospitalization within the past six months for respiratory failure in patients with chronic respiratory disease. (PaCO<sub>2</sub> greater than 50 mmHg or PaO<sub>2</sub> less than 55 mmHg or O<sub>2</sub>-Sat < 88% on FiO<sub>2</sub> = .21).
6. Chronic restrictive, obstructive, neuromuscular, chest wall or pulmonary vascular disease resulting in severe exercise restriction, e.g., unable to climb stairs or perform household duties, secondary polycythemia, severe pulmonary hypertension (mean PAP greater than 40 mmHg), or respirator dependency.

## C Trophic Feeding Protocol



## D Full-calorie Feeding Protocol



## E Time-Events Schedule

Measurement/Event	Day 0	1	2	3	4	5	6	7	8	9	10	11	12	14	21	28	60
Demographics, History & Physical, Height, Weight	X																
Etiology of ARDS, site of sepsis if septic etiology	X																
APACHE III Score <sup>C</sup>	X																
HCG (in females)	X																
Vital Signs (HR, SBP, DBP, Temp °C) *	X	X	X	X	X	X	X	X	X	X	X	X					
Central Venous Pressure *	A	A	A	A	A	A	A	A	A	A	A	A					
Fluids (In and Out) *	X	X	X	X	X	X	X	X									
Brussels Score <sup>B</sup> ~	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Glasgow Coma Scale	X							X									X**
Ventilator Parameters (including FiO <sub>2</sub> ) *#	X	X	X	X	X		X						X		X	X	
Arterial Blood Gases (PaO <sub>2</sub> , PaCO <sub>2</sub> , pH) and SpO <sub>2</sub>	X	A	A	A	A		A						A		A	A	
Serum Glucose, Na+, K+, HCO <sub>3</sub> -, Hgb	X	A	A	A	A	A	A	A	A	A	A	A	A				
Creatinine, Platelets, Bilirubin, BUN Hct,	X																
Chest X-ray (# quadrants for lung injury score)	A	A	A	A	A	A	A	A	A	A	A						
Record Sedatives, narcotics, pressors * (Y/N)	X	X	X	X	X	X	X	X	X	X	X	X	X				
Serum magnesium and phosphorus	X	X	A	X	A	A	A	A	X	A	A	A	A				
Total Protein and Albumin	X	X	A	A	A	A	A	X	A	A	A	A	X				
Ventilator-Associated Pneumonia assessment <sup>v</sup>	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	
Insulin dose at time of glucose level	A	A	A	A	A	A	A	A	A	A	A	A	A				
Location of Feeding tube (e.g., gastric, post-pyloric) *	X	A	A	A	A	A	A	A	A	A	A	A	A				
Volume of tube feeds / Calories delivered *		X	X	X	X	X	X	X	X	X	X	X	X				
Number and type of Gastrointestinal Intolerances *		X	X	X	X	X	X	X	X	X	X	X	X				
Pro-kinetic agents, anti-diarrheals, anti-emetics * (Y/N)	X	X	X	X	X	X	X	X	X	X	X	X	X				
Serum fatty acids *** (no longer required)	X			X			X						X				
Plasma for Cytokines IL-6 and IL-8	X			X			X						X				
Urine leukotriene B and isoprostane metabolites	X			X			X										
Whole blood for DNA	X																
Episode of bacteremia (record positive blood cultures) *		A	A	A	A	A	A	A	A	A	A	A	A	A			
<i>Clostridium difficile</i> diarrhea tests		A	A	A	A	A	A	A	A	A	A	A	A	A			
Study Drug Administration Record *	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		
Vital Status §																	X

X=Required

A=When available

<sup>C</sup>=Labs not available in the 24 hours before randomization must be obtained

<sup>v</sup> = VAP assessment from available CXR, sputum culture, gram stain and WBC until extubated or day 28, whichever occurs first

\*= Data gathered at times indicated or until 48 hours UAB, whichever occurs first

\*\*=On day 28 or hospital discharge date

\*\*\*=Collect in the first 30 patients of the placebo and study emulsion groups.

<sup>B</sup>=Records clinically available creatinine, platelets, bilirubin, SBP and vasopressor use

~=Data gathered on days 0-28 or until d/c from study hospital

#=Measure during reference period (0600-1000); other values may be obtained closest to 0800 on the specified calendar date

§=Measure at 90 days and 12 months as part of Long Term outcome.

## F Adverse Events

### 1. Procedures for Reporting Adverse Events

Assuring patient safety is an essential component of this protocol. Each participating investigator has primary responsibility for the safety of the individual participants under his or her care. The Principal Investigator will evaluate all adverse events. The Study Coordinator must view patient records for possible adverse events throughout the study period. All adverse events occurring within the study period must be reported in the participants' case report forms.

Investigators will report all *serious, unexpected, and study-related* adverse events to the Clinical Coordinating Center within 24 hours. The local Institutional Review Board must also be notified in a timely manner. The investigator will then submit a detailed written report to the Clinical Coordinating Center and the local Institutional Review Board no later than 5 days after the investigator discovers the event.

### 2. Definitions of Adverse Events

A *serious* adverse event is any event that is fatal or immediately life threatening, is permanently disabling, or severely incapacitating, or requires or prolongs inpatient hospitalization. Important medical events that may not result in death, be life threatening, or require hospitalization may be considered serious adverse events when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed above.

Life-threatening means that the patient was, in the view of the investigator, at immediate risk of death from the reaction as it occurred. This definition does not include a reaction that, had it occurred in a more serious form, might have caused death. Assessment of the cause of the event has no bearing on the assessment of the event's severity.

An *unexpected* event is any experience not identified by the type, severity, or frequency in the current study protocol or an event that is unexpected in the course of treatment for ALI or ARDS.

Adverse events will be considered to be study-related if the event follows a reasonable temporal sequence from a study procedure and could readily have been produced by the study procedure.

Organ failures related to ALI or ARDS or the patient's underlying condition should not be reported as adverse events *if the investigator determines the outcomes were not study solution or procedure-related* since they are systematically captured by the protocol data collection.

The following protocol-specified events should always be reported as adverse events:

- a. Hypersensitivity to enteral feeds
- b. Hypersensitivity to omega-3 fatty acids
- c. Intestinal ischemia or infarction
- d. Severe bleeding (defined as any central nervous system bleeding or any bleeding event that leads to the administration of three or more units of packed red blood cells per day for two consecutive days).

## G Ventilator Procedures

### G.1 Ventilator Management

A modified, simplified version of the ARDS Network lung protective lower tidal volume strategy will be used in this trial. This strategy, which was associated with unprecedented low mortality rates in three previous ARDS Network trials (ARMA, ALVEOLI, and FACTT), will ensure that study subjects receive the beneficial effects of lung protection as part of their participation in this trial (Brower, 2004; The Acute Respiratory Distress Syndrome Network, 2000). ARDS Network personnel have substantial experience in the application of this protocol from the three completed trials noted above.

1. Any mode of ventilation capable of delivering the prescribed tidal volume (6ml/kg PBW, +/- 2ml/kg) may be used, provided the  $V_T$  target is monitored and adjusted appropriately. During APRV, tidal volume is defined as the sum of the volume that results from the ventilator pressure-release and an estimation of the average spontaneous  $V_T$ .

2. Tidal Volume ( $V_t$ ) Goal: 6 ml / kg PBW

Predicted body weight (PBW) is calculated from age, gender, and height (heel to crown) according to the following equations:

$$\text{Males: PBW (kg)} = 50 + 2.3 [\text{height (inches)} - 60]$$

$$\text{Females: PBW (kg)} = 45.5 + 2.3 [\text{height (inches)} - 60]$$

3. Measure and record inspiratory plateau pressure (Pplat) according to ICU routine (at least every four hours and after changes in  $V_t$  and PEEP recommended)
4. If  $P_{plat} > 30$  cm H<sub>2</sub>O, reduce  $V_t$  to 5 ml / kg and then to 4 ml / kg PBW if necessary to decrease Pplat to  $\leq 30$  cm H<sub>2</sub>O.
5. If  $V_t < 6$  ml / kg PBW and  $P_{plat} < 25$  cm H<sub>2</sub>O, raise  $V_t$  by 1 ml / kg PBW to a maximum of 6 ml / kg.
6. If "severe dyspnea" (more than 3 double breaths per minute or airway pressure remains at or below PEEP level during inspiration), then raise  $V_t$  to 7 or 8 ml / kg PBW if Pplat remains below 30 cm H<sub>2</sub>O. If Pplat exceeds 30 cm H<sub>2</sub>O with  $V_t$  of 7 or 8 ml / kg PBW, then revert to lower  $V_t$  and consider more sedation.
7. If  $pH < 7.15$ ,  $V_t$  may be raised and Pplat limit suspended (not required).
8. Oxygenation target: 55 mmHg  $<$  PaO<sub>2</sub>  $<$  80 mm Hg or 88%  $<$  SpO<sub>2</sub>  $<$  95%. When both PaO<sub>2</sub> and SpO<sub>2</sub> are available simultaneously, the PaO<sub>2</sub> criterion will take precedence.
9. Minimum PEEP = 5 cm H<sub>2</sub>O
10. Adjust FiO<sub>2</sub> or PEEP upward within 5 minutes of consistent measurements below the oxygenation target range



11. Adjust FiO<sub>2</sub> or PEEP downward within 30 minutes of consistent measurements above the oxygenation target range.
12. There are no requirements for maintaining a specific PEEP to FiO<sub>2</sub> ratio. The lower PEEP / higher FiO<sub>2</sub> table represents a consensus approach developed by ARDS Network investigators in 1995. The higher PEEP / lower FiO<sub>2</sub> table (ALVEOLI) yielded equivalent results in a randomized trial (Brower, 2004) and would be acceptable and perhaps preferable in patients who appear to respond with substantial increase in arterial oxygenation in the transition from lower to higher PEEP.

**Lower ELV/Higher FiO<sub>2</sub> Treatment Group**

FiO <sub>2</sub>	.30	.40	.40	.50	.50	.60	.70	.70	.70	.80	.90	.90	.90	1.0
PEEP	5	5	8	8	10	10	10	12	14	14	14	16	18	18-24

**Higher ELV/Lower FiO<sub>2</sub> Study Group**

FiO <sub>2</sub>	.30	.30	.30	.30	.30	.40	.40	.50	.50	.50 – .80	.80	.90	1.0	1.0
PEEP	5	8	10	12	14	14	16	16	18	20	22	22	22	24

(Levels of PEEP in these FiO<sub>2</sub> / PEEP scales represent levels set on the ventilator, not levels of total-PEEP, auto-PEEP, or intrinsic-PEEP.)

13. No specific rules for respiratory rate, but incremental increase in the RR to maximum set rate of 35 if pH < 7.30.
14. No specific rules about I:E. Recommend that duration of Inspiration be ≤ duration of Expiration.
15. Bicarbonate is allowed (neither encouraged nor discouraged) if pH < 7.30.

Changes in more than one ventilator setting driven by measurements of PaO<sub>2</sub>, pH, and Pplat may be performed simultaneously, if necessary.

## **G.2 Weaning**

### **G.2.1 Commencement of Weaning**

Patients will be assessed for the following weaning readiness criteria each day between 0600 and 1000. If a patient procedure, test, or other extenuating circumstance prevents assessment for these criteria between 0600 and 1000, then the assessment and initiation of subsequent weaning procedures may be delayed for up to six hours.

- (a) At least 12 hours since enrollment in the trial.
- (b) FiO<sub>2</sub> ≤ 0.40 and PEEP ≤ 8 cm H<sub>2</sub>O or FiO<sub>2</sub> ≤ 0.50 and PEEP = 5 cm H<sub>2</sub>O
- (c) Values of both PEEP and FiO<sub>2</sub> ≤ values from previous day (comparing Reference Measurement values, section 6.3).
- (d) Not receiving neuromuscular blocking agents and without neuromuscular blockade

- (e) Patient exhibiting inspiratory efforts. If no efforts are evident at baseline, ventilator set rate will be decreased to 50 % of baseline level for up to 5 minutes to detect inspiratory efforts.
- (f) Systolic arterial pressure  $\geq 90$  mm Hg without vasopressor support ( $\leq 5$  mcg / kg / min dopamine or dobutamine will not be considered a vasopressor).

### **G.2.2 Spontaneous Breathing Trial Procedure and Assessment for Unassisted Breathing**

If criteria a-f above are met, then initiate a trial of up to 120 minutes of spontaneous breathing with  $F_{iO_2} \leq 0.5$  using any of the following approaches:

1. Pressure support  $\leq 5$ cm H<sub>2</sub>O, PEEP  $\leq 5$ cm H<sub>2</sub>O
2. CPAP  $\leq 5$  cm H<sub>2</sub>O
3. T-piece
4. Tracheostomy mask

Monitor for tolerance using the following:

1. SpO<sub>2</sub>  $\geq 90\%$  and / or PaO<sub>2</sub>  $\geq 60$  mmHg
2. Mean spontaneous tidal volume  $\geq 4$  ml / kg PBW (if measured)
3. Respiratory Rate  $\leq 35$  / min
4. pH  $\geq 7.30$  (if measured)
5. No respiratory distress (defined as 2 or more of the following):
  - a. Heart rate  $\geq 120\%$  of the 0600 rate ( $\leq 5$  min at  $> 120\%$  may be tolerated)
  - b. Marked use of accessory muscles
  - c. Abdominal paradox
  - d. Diaphoresis
  - e. Marked subjective dyspnea.

If any of the goals 1-5 are not met, revert to previous ventilator settings or to PS + 10 cm H<sub>2</sub>O with Positive End-expiratory Pressure and FiO<sub>2</sub> = previous settings and reassess for weaning the next morning.

The clinical team may decide to change mode of support during spontaneous breathing (PS = 5, CPAP, tracheostomy mask, or T-piece) at any time.

### **G.2.3 Decision to remove ventilatory support**

For intubated patients, if tolerance criteria for spontaneous breathing trial (1-5 above) are

met for at least 30 minutes, the clinical team may decide to extubate. However, the spontaneous breathing trial can continue for up to 120 minutes if tolerance remains in question. If any of criteria 1-5 are not met during unassisted breathing (or 120 minutes has passed without clear tolerance), then the ventilator settings that were in use before the attempt to wean will be restored and the patient will be reassessed for weaning (see section G.2.1) the following day.

### **G.3 Definition of Unassisted Breathing**

- (a) Extubated with face mask, nasal prong oxygen, or room air, OR
- (b) T-tube breathing, OR
- (c) Tracheostomy mask breathing, OR
- (d) CPAP  $\leq 5$  without PS or IMV assistance

### **G.4 Completion of Ventilator Procedures**

Patients will be considered to have completed the study ventilator procedures if any of the following conditions occur:

- a. Death
- b. Hospital discharge
- c. Alive 28 days after enrollment

If a patient requires positive pressure ventilation after a period of unassisted breathing, the study ventilator procedures will resume unless the patient was discharged from the hospital or  $> 28$  days elapsed since enrollment.

### **G.5 Removal from the Ventilator Management Protocol**

Patients may be removed from the 6 ml / kg tidal volume ventilation requirement if they develop neurologic conditions where hypercapnia would be contraindicated (e.g., intracranial bleeding, GCS  $\leq 8$ , cerebral edema, mass effect [midline shift on CT scan], papilledema, intracranial pressure monitoring, fixed pupils).

## H Conservative Fluid Management Approach

This fluid protocol captures the primary positive outcome of the FACTT trial on increasing ventilator free days. This protocol should be initiated within four hours of randomization in enrolled patients, and continued until UAB or study day 7, whichever occurs first.

1. Discontinue maintenance fluids.
2. Continue medications and nutrition.
3. Manage electrolytes and blood products per usual practice.
4. For shock, use any combination of fluid boluses<sup>#</sup> and vasopressor(s) to achieve MAP  $\geq$  60 mmHg as fast as possible. Wean vasopressors as quickly as tolerated beginning four hours after blood pressure has stabilized.
5. Withhold diuretic therapy in renal failure<sup>§</sup> and until 12 hours after last fluid bolus or vasopressor given.

CVP (recommended)	PAOP (optional)	MAP $\geq$ 60 mm Hg AND off vasopressors for $\geq$ 12 hours	
		Average urine output < 0.5 ml/kg/hr	Average urine output $\geq$ 0.5 ml/kg/hr
>8	> 12	Furosemide* Reassess in 1 hour	Furosemide* Reassess in 4 hours
4-8	8-12	Give fluid bolus as fast as possible <sup>#</sup> Reassess in 1 hour	No intervention Reassess in 4 hours
< 4	< 8		

§ Renal failure is defined as dialysis dependence, oliguria with serum creatinine > 3mg/dl, or oliguria with serum creatinine 0-3 with urinary indices indicative of acute renal failure.

<sup>#</sup> Recommended fluid bolus= 15 mL / kg crystalloid (round to nearest 250 mL) or 1 Unit packed red cells or 25 grams albumin

\* Recommended Furosemide dosing = begin with 20 mg bolus or 3 mg / hr infusion or last known effective dose. Double each subsequent dose until goal achieved (oliguria reversal or intravascular pressure target) or maximum infusion rate of 24 mg / hr or 160 mg bolus reached. Do not exceed 620 mg / day. Also, if patient has heart failure, consider treatment with dobutamine.

## **I Genetic Testing**

Portions of the blood specimens as specified in this protocol will be used for genetic analyses either for beta-receptor polymorphisms as part of an ancillary study, or for future genetic studies of ARDS that are presently undefined. ALI is a complex inflammatory condition of the lungs, and many of the inflammatory pathways thought to be involved in lung injury are associated with genetic polymorphisms. It is likely that there are, as yet undetermined, important gene/environment interactions that impact on clinical outcome. Thus it is important to collect and store DNA from large, carefully described cohorts of patients with ALI to facilitate discovery in this field with the aim to better understand the pathogenesis of ARDS and how treatment may be tailored to individual patient needs.

Genetic analysis will involve, in part, the analysis of genomic DNA and will attempt to link genotypic information to the extensive phenotypic information measured as part of this study. A layered informed consent will be used to obtain the study subjects' consent for genetic testing as follows: 1) consent for genetic studies related to ARDS, or; 2) consent for future studies not necessarily related to ARDS. The level of consent for testing (e.g. none, for ARDS studies, for future studies, or all studies) will be recorded in the Case Report Forms and stored in the Clinical Coordinating Center Data Base. All patients who recover decision-making capacity will be approached for written re-consent for genetic testing.

Two 7.5 ml EDTA plastic monovette tubes will be used to collect up to 10 ml of blood on each patient with consent for genetic testing. Samples will be labeled with pre-printed label with the subjects ARDSNet study number. DNA extraction will be done centrally.

Following extraction, DNA will be sent to a central repository to be stored (as described below). DNA will first be stored the extraction laboratory for seven years and then shipped to the central repository. Random number will identify samples during shipment, extraction, and storage in the central repository. In the future, when approved studies for genetic testing are received at the CCC, the CCC will identify samples that have the necessary level of informed consent for genetic testing. The CCC will then instruct the repository to prepare the appropriate samples for shipment. The key relating the ARDSNet study number to the specimen number will be kept at the CCC in a locked file. The CCC does not record nor store unique patient identifiers (such as initials, date of birth, hospital record numbers, addresses, phone numbers, etc.) in the data base. All data released by the CCC for genetic studies will be linked to the specimen but will be de-identified. The link (key) between the de-identified database and the patient will be removed two years after the primary publication.

Should patients or surrogates revoke their consent for genetic testing, the clinical sites will notify the CCC. The CCC will then contact the repository and request that all samples collected for genetic analysis for that patient be destroyed. Confirmation of destruction of samples will be sent to the CCC and forwarded to the clinical site.

## **J De-identified Data Elements for Screened, Non-Enrolled Subjects**

- Was onset of ALI acute?
- Did frontal CXR show bilateral infiltrates consistent with pulmonary edema?
- Number of quadrants with opacities?
- Is patient intubated?
- PaO<sub>2</sub>
- FiO<sub>2</sub>
- Was there evidence of left atrial hypertension?
- Month of the year that patient met screening criteria (1-12).
- Gender
- Ethnicity
- Age (if age >89, 89 will be entered for age)
- Patient location (e.g. MICU, SICU, etc.) and if regularly screened
- Reason(s) patient excluded from study.
- If not excluded, not enrolled, why?
- Lung injury category (e.g. sepsis, pneumonia)
- If lung injury category=sepsis, site of infection

## K Long Term Outcomes

### K.1 Phone Surveys for Survivors from All 12 ARDSNet Study Sites

Table 1 summarizes the proposed measurement instruments and their rationale for each of the outcome domains evaluated in the phone-based assessments of ALI survivors from all ARDSNet study sites. These domains and instruments were determined based on a comprehensive assessment performed by the ARDSNet Long-Term Outcomes Committee and by the investigators for this proposed study.

**Table 1. Phone assessments of ALI survivors from all 12 ARDSNet study sites at 6 and 12 months**

Outcome Domain	Instrument	Rationale	No. of items; Time Req'd; Scale
Mortality	Custom (date & cause of death)*	- Used in existing long-term ALI study (2)	3 item; <1 min.
Physical function	Functional Performance Inventory - Short Form (FPI-SF)	-Developed in chronic pulmonary patients -Comprehensive, reliable and valid (11;12)	32 items; 5 minutes; Continuous
<b>Mental health</b>			
a) Depression & General Anxiety	Hospital anxiety & depression (HAD) scale (13)	-Most widely used survey in medical patients(14) -Separate subscale for depression & anxiety -Reliable and validated in medical patients (14) -Highly correlated with psychiatric evaluation (13;15)	14 items; 5 minutes (2) Continuous
b) Post-traumatic stress disorder	Impact of Events Scale – Revised (IES-R) (16)	-IES is the most commonly used instrument for assessing PTSD in the ICU (15) -Revised version (IES-R) follows DSM-IV (17) criteria -Reliable and valid (16;18)	22 items; 3 minutes (2) Continuous
Cognitive status	Telephone Mini-Mental State Examination (TMMSE) (19;20)	-MMSE is the most widely used instrument -TMMSE is designed specifically for phone use -Reliable and valid (19;20)	16 items; 5 minutes; Continuous
<b>Health-related quality of life</b>			
a) Generic	1. SF-36 version 2 (21)	-Most widely used instrument, esp in ALI (1-3;6-7) -Reliable and validated in ICU patients (23) -US population norms available (21)	36 items; 6 minutes; Continuous
	2. EQ-5D (EuroQOL) (22)	-Feasible for patients with inattention& fatigue (6;22) -Recommended for use in ICU patients (5) -Provides utility estimate with US norms (24)	6 items; 2 minutes (2) Continuous
b) Fatigue	Functional Assessment of Chronic Illness Therapy (FACIT)	-Designed for patients with chronic illness -Assesses both functional & emotional impact (25;26) -Reliable and validated (27;28)	13 items; 3 minutes (25) Continuous
Return to work	Custom instrument	-Developed & used in large cohort of ALI survivors (2)	12 item; 2 min. Categorical
Health care utilization	University of Toronto ARDS Outcome study instrument (4)	-Developed and used in large longitudinal cohort of ALI survivors (4)	27 items; 8 minutes; Continuous

\* Also will be determined from a National Death Index via participant's Social Security Number.

Administration of phone surveys will be centralized at 2 sites: Johns Hopkins and LDS Hospital, where the 2 Principal Investigators are affiliated. Being in different time zones, this 2-site approach will allow flexibility in accessing patients across the US while also concentrating our oversight activities. Manuals of Operations will be used for training, reference and quality assurance review.

#### **NOTES:**

(1) Estimated time for completion. This was based on pilot testing, published estimates and the experience of the ARDS Network investigators. The full telephone interview will be piloted prior to implementation.

(2) Return to Work assessment. There are no pre-existing comprehensive survey instruments for measuring return to work and work disability in patients with lung disease. We derived our custom-made instrument from an approach used by one member of the Long-term Outcomes Committee (Dr. Eisner and colleagues) to measure work disability in asthma and COPD.

#### **K.2 Statistical Considerations for Long Term Outcomes**

A number of dichotomous and continuous measures of long-term efficacy of the treatment will be analyzed.

##### **Dichotomous measures:**

- 1) Survival times will be compared for the treatment arms using log rank test.
- 2) Proportions of patients alive without major disabilities will be compared between the treatment arms using Cochran-Mantel-Haenszel test. Major disability is defined for surviving patients that are prevented from working due to a respiratory condition.
- 3) Proportions of patients alive without disability in activities of daily living (ADL) or instrumental activities of daily living (IADL) will be compared across treatment arms using Cochran-Mantel-Haenszel test. Major disability ADL and IADL are defined based on functional performance inventory for a patient who has at least one activity in the “body care” and “maintaining household” subscales, respectively, that s/he cannot perform at all due to health reasons or does it with much difficulty.

Each of the comparisons will be done based on the data collected at 6 months, and 1-year follow up times.

##### **Continuous measures:**

- 1) Primary measure of disability defined by functional performance inventory.
- 2) Eight subscales and two summary measures of the SF-36 instrument
- 3) Depression measure defined by Beck Depression Inventory II
- 4) Cognitive measure

Continuous measures will be analyzed using analysis of variance stratified by the treatment arm.

Each of the comparisons we will be done based on the data collected at 6 months, and at 12 months follow up times. We will compare the raw continuous measures in the groups of



patients available for the follow up. There is a concern that those patients that survive and are contactable to obtain information will potentially belong to different populations for different treatment arms. If true, this will make comparison between the treatment arms no longer randomized. To address this we will compare the treatment arms using survival average causal effect (SACE). This method (Hayden 2005) uses concepts of casual inference by adjusting the estimates of the population parameters based on the model covariates. First the expected probabilities of survival and ability to contact and obtain information from a patient are computed using logistic regression. Then estimates are weighted by these computed survival and contactability to correct for potential differences in the patient populations across treatment arms selected by survival and contactability of patients. The model depends on the assumption that conditional on the values of the covariates the probabilities of a patient surviving and being contactable are independent across treatment arms. The effects of this assumption will be evaluated via a sensitivity analysis.

### **K.3 Citations for M1 (Choice of survey instruments)**

1. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al Saida F, Cooper AB, Guest CB, Mazer CD, Mehta S, Stewart TE, Barr A, Cook D, Slutsky AS. One-year outcomes in survivors of the acute respiratory distress syndrome. *N.Engl.J.Med.* 2003;683-93.
2. Needham DM, Dennison CR, Dowdy DW, Mendez-Tellez PA, Ciesla N, Desai SV, Sevransky J, Shanholtz C, Scharfstein D, Herridge MS, Pronovost PJ. Study protocol: The Improving Care of Acute Lung Injury Patients (ICAP) study. *Crit Care* 2005;R9 <http://ccforum.com/content/10/1/R9>.
3. Hopkins RO, Weaver LK, Collingridge D, Parkinson RB, Chan KJ, Orme JF, Jr. Two-year cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome. *Am.J Respir.Crit Care Med* 2005;340-7.
4. Cheung AM, Tansey CM, Tomlinson G, Diaz-Granados N, Matte A, Barr A, Mehta S, Mazer CD, Guest CB, Stewart TE, Al Saida F, Cooper AB, Cook D, Slutsky AS, Herridge MS. Two-year outcomes, health care utilization and costs in survivors of the acute respiratory distress syndrome. *American Journal of Respiratory and Critical Care Medicine* 2006;In press.
5. Angus DC, Carlet J. Surviving intensive care: a report from the 2002 Brussels Roundtable. *Intensive Care Med.* 2003;368-77.
6. Dowdy DW, Eid MP, Sedrakyan A, Mendez-Tellez PA, Pronovost PJ, Herridge MS, Needham DM. Quality of life in adult survivors of critical illness: A systematic review of the literature. *Intensive Care Medicine* 2005;611-20.
7. Dowdy DW, Eid MP, Dennison CR, Mendez-Tellez PA, Herridge MS, Guallar E, Pronovost PJ, Needham DM. Quality of life after acute respiratory distress syndrome: a meta-analysis. *Intensive Care Medicine* 2006;1115-24.

8. Leidy NK. Psychometric properties of the functional performance inventory in patients with chronic obstructive pulmonary disease. *Nurs.Res.* 1999;20-8.
9. Leidy NK, Knebel A. Clinical validation of the Functional Performance Inventory in patients with chronic obstructive pulmonary disease. *Respiratory Care* 1999;932-9.
10. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr.Scand.* 1983;361-70.
11. Herrmann C. International experiences with the Hospital Anxiety and Depression Scale--a review of validation data and clinical results. *J Psychosom.Res.* 1997;17-41.
12. Hayes JA, Black NA, Jenkinson C, Young JD, Rowan KM, Daly K, Ridley S. Outcome measures for adult critical care: a systematic review. *Health Technol.Assess.* 2000;1-111.
13. Weiss DS. The Impact of Event Scale - Revised. In: Wilson JP, Keane TM, eds. *Assessing Psychological Trauma and PTSD: A Practitioner's Handbook.* New York: Guilford Press, 2004;168-189.
14. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders.* Washington, D.C.: American Psychiatric Association, 1994.
15. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. *Psychosom.Med* 1979;209-18.
16. Newkirk LA, Kim JM, Thompson JM, Tinklenberg JR, Yesavage JA, Taylor JL. Validation of a 26-point telephone version of the Mini-Mental State Examination. *J Geriatr.Psychiatry Neurol.* 2004;81-7.
17. Roccaforte WH, Burke WJ, Bayer BL, Wengel SP. Validation of a telephone version of the mini-mental state examination. *J Am.Geriatr.Soc.* 1992;697-702.
18. Ware JE, Jr., Kosinski M, Dewey JE. *How to Score Version 2 of the SF-36 Health Survey.* Lincoln, RI: QualityMetric Incorporated, 2000.
19. The EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. *Health Policy* 1990;199-208.
20. Chrispin PS, Scotton H, Rogers J, Lloyd D, Ridley SA. Short Form 36 in the intensive care unit: assessment of acceptability, reliability and validity of the questionnaire. *Anaesthesia* 1997;15-23.
21. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. *Medical Care* 2005;203-20.
22. Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. *Cancer* 2002;528-38.

23. Mallinson T, Cella D, Cashy J, Holzner B. Giving meaning to measure: linking self-reported fatigue and function to performance of everyday activities. *J Pain Symptom Manage.* 2006;229-41.
24. Cella D, Nowinski CJ. Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. *Arch.Phys.Med Rehabil.* 2002;S10-S17.
25. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. *Health Qual.Life Outcomes.* 2003;79.
26. Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Medical Care* 1996;220-33.
27. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. *Can.Med Assoc.J* 1985;919-23.
28. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. *Am.J Respir.Crit Care Med* 1998;1384-7.

## L. Data and Safety Monitoring Board

The principal role of the DSMB is to regularly monitor data from this trial, review and assess the performance of its operations, and make recommendations, as appropriate, to the NHLBI with respect to:

- Review of adverse events
- Interim results of the study for evidence of efficacy or adverse events
- Possible early termination of the trial because of early attainment of study objectives, safety concerns, or inadequate performance
- Possible modifications in the clinical trial protocol
- The performance of individual centers

The NHLBI ARDS Network DSMB is appointed by the Director, NHLBI. The DSMB reviews all new protocols for safety following review by an independent NHLBI Protocol Review Committee. The DSMB will consist of members with expertise in acute lung injury, biostatistics, ethics, and clinical trials. Ad hoc members have been appointed with particular expertise where necessary. Appointment of all members is contingent upon the absence of any conflicts of interest. All the members of the DSMB are voting members. The DSMB will review data prepared by the CCC. Decisions regarding issues such as stopping guidelines or whether the DSMB may at times remain blinded to study group identity will be made jointly by the DSMB members and the NHLBI representatives. The Principal Investigator and the Medical Monitor of the CCC will be responsible for the preparation of DSMB and adverse event reports and may review unblinded data. DSMB meetings will be scheduled by the NHLBI at intervals as described in section 7, and the DSMB will review the protocol during its first meeting. When appropriate, conference calls may be held in place of face-to-face meetings. Recommendations to end, modify, or continue a trial will be prepared by the DSMB executive secretary for review by Director, NHLBI, no more than two working days after a DSMB meeting. When appropriate, conference calls may be held in place of face-to-face meetings. Recommendations for major changes, such as stopping, will be communicated immediately, and followed by a written summary. The NHLBI will act on recommendations expeditiously; the NHLBI Project Officer or Program Scientist will communicate the recommendations promptly to the ARDS Network Steering Committee and the CCC with instructions for reporting to local IRBs when appropriate. The executive secretary of the DSMB will be responsible for preparing the minutes for each meeting or conference call. Details of the NHLBI policies regarding DSMBs can be found at the following URL: [http://www.nhlbi.nih.gov/funding/policies/dsmb\\_inst.htm](http://www.nhlbi.nih.gov/funding/policies/dsmb_inst.htm)

The ARDS Network Steering Committee is comprised of the Principal Investigators and Co-investigators of all the Clinical sites, the CCC, and the NHLBI Project Officer who represents the NHLBI. All sites and the CCC have one vote, which is advisory to the NHLBI.

## M. AUDIT Questionnaire

### The Alcohol Use Disorders Identification Test (Babor, 1992)

The Alcohol Consumption Questionnaire is important to administer because there is a common association between alcohol abuse and Acute Lung Injury (ALI) (Moss, 1996). It will be important to have this information for a subgroup analysis. Knowledge of alcohol abuse will also help the primary team better care for the patient and improve patient outcome, as there are alcohol specific disorders in critically ill patients that often are not diagnosed and therefore not treated effectively. This survey will not be completed on subjects less than 18 years of age.

<p>1. How often do you have a drink containing alcohol?</p> <p>(0) Never [Skip to Qs 9-10]            (1) Monthly or less            (2) 2 to 4 times a month            (3) 2 to 3 times a week            (4) 4 or more times a week</p> <input type="checkbox"/>	<p>6. How often during the last year have you needed a first drink in the morning to get yourself going after a heavy drinking session?</p> <p>(0) Never            (1) Less than monthly            (2) Monthly            (3) Weekly            (4) Daily or almost daily</p> <input type="checkbox"/>
<p>2. How many drinks containing alcohol do you have on a typical day when you are drinking?</p> <p>(0) 1 or 2            (1) 3 or 4            (2) 5 or 6            (3) 7, 8, or 9            (4) 10 or more</p> <input type="checkbox"/>	<p>7. How often during the last year have you had a feeling of guilt or remorse after drinking?</p> <p>(0) Never            (1) Less than monthly            (2) Monthly            (3) Weekly            (4) Daily or almost daily</p> <input type="checkbox"/>
<p>3. How often do you have six or more drinks on one occasion?</p> <p>(0) Never            (1) Less than monthly            (2) Monthly            (3) Weekly            (4) Daily or almost daily</p> <p><i>Skip to Questions 9 and 10 if Total Score for Questions 2 and 3 = 0</i></p> <input type="checkbox"/>	<p>8. How often during the last year have you been unable to remember what happened the night before because you had been drinking?</p> <p>(0) Never            (1) Less than monthly            (2) Monthly            (3) Weekly            (4) Daily or almost daily</p> <input type="checkbox"/>
<p>4. How often during the last year have you found that you were not able to stop drinking once you had started?</p> <p>(0) Never            (1) Less than monthly            (2) Monthly            (3) Weekly            (4) Daily or almost daily</p> <input type="checkbox"/>	<p>9. Have you or someone else been injured as a result of your drinking?</p> <p>(0) No            (2) Yes, but not in the last year            (4) Yes, during the last year</p> <input type="checkbox"/>
<p>5. How often during the last year have you failed to do what was normally expected from you because of drinking?</p> <p>(0) Never            (1) Less than monthly            (2) Monthly            (3) Weekly            (4) Daily or almost daily</p> <input type="checkbox"/>	<p>10. Has a relative or friend or a doctor or another health worker been concerned about your drinking or suggested you cut down?</p> <p>(0) No            (2) Yes, but not in the last year            (4) Yes, during the last year</p> <input type="checkbox"/>
<p style="text-align: right;">Record total of specific items here <input type="checkbox"/></p> <p><i>If total is greater than recommended cut-off, consult User's Manual.</i></p>	

## References

1. Abbey, M, Belling, GB, et al. (1993). Oxidation of low-density lipoproteins: Intraindividual variability and the effect of dietary linoleate supplementation. *Am J Clin Nutr.* 57(3): 391-398.
2. Abraham, E (2000). Coagulation abnormalities in acute lung injury and sepsis. *Am J Respir Cell Mol Biol* 22(4): 401-404.
3. Adam, S and Batson, S (1997). A study of problems associated with the delivery of enteral feed in critically ill patients in five icus in the uk. *Intensive Care Med.* 23(3): 261-266.
4. Afanas'ev, IB (2005). Free radical mechanisms of aging processes under physiological conditions. *Biogerontology.* 6(4): 283-290.
5. American College of Physicians (1989). Cognitively impaired subjects. *Ann Int Med* 111: 843-8.
6. Angus, DC, Musthafa, AA, et al. (2001). Quality-adjusted survival in the first year after the acute respiratory distress syndrome. *Am J Respir Crit Care Med* 163(6): 1389-94.
7. Arndt, P and Abraham, E (2001). Immunological therapy of sepsis: Experimental therapies. *Intensive Care Med.* 27 Suppl 1: S104-S115.
8. Artinian, V, Krayem, H, et al. (2006). Effects of early enteral feeding on the outcome of critically ill mechanically ventilated medical patients. *Chest* 129(4): 960-967.
9. Babor TF, de la Fuente JR, Saunders J, Grant M. The Alcohol Use Disorders Identification Test: Guidelines for use in primary health care. World Health Organization (1992).
10. Barham, JB, Edens, MB, et al. (2000). Addition of eicosapentaenoic acid to gamma-linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans. *J Nutr* 130(8): 1925-1931.
11. Barr, J, Hecht, M, et al. (2004). Outcomes in critically ill patients before and after the implementation of an evidence-based nutritional management protocol. *Chest* 125(4): 1446-1457.
12. Bernard, GR (1997). The brussels score. *Sepsis* 1: 43-44.
13. Bernard, GR (2005). Acute respiratory distress syndrome: A historical perspective. *Am J Respir Crit Care Med.* 172(7): 798-806.
14. Bernard, GR, Korley, V, et al. (1991). Persistent generation of peptido leukotrienes in patients with the adult respiratory distress syndrome. *Am Rev Respir Dis.* 144(2): 263-267.

15. Bernard, GR, Vincent, JL, et al. (2001). Efficacy and safety of recombinant human activated protein c for severe sepsis. *N Engl J Med* 344(10): 699-709.
16. Bernard, GR, Wheeler, AP, et al. (1997). A trial of antioxidants n-acetylcysteine and procysteine in ards. The antioxidant in ards study group. *Chest* 112(1): 164-172.
17. Bernard, GR, Wheeler, AP, et al. (1997). The effects of ibuprofen on the physiology and survival of patients with sepsis. The ibuprofen in sepsis study group. *N Engl J Med* 336(13): 912-918.
18. Breil, I, Koch, T, et al. (1996). Alteration of n-3 fatty acid composition in lung tissue after short-term infusion of fish oil emulsion attenuates inflammatory vascular reaction. *Crit Care Med.* 24(11): 1893-1902.
19. Brower, RG, Lanken, PN, et al. (2004). Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. *N Engl J Med* 351(4): 327-36.
20. Buchman, AL, Moukarzel, AA, et al. (1995). Parenteral nutrition is associated with intestinal morphologic and functional changes in humans. *J Parenter Enteral Nutr.* 19(6): 453-460.
21. Burrin, DG, Stoll, B, et al. (2000). Minimal enteral nutrient requirements for intestinal growth in neonatal piglets: How much is enough? *71(6): 1603-10.*
22. Caironi, P, Ichinose, F, et al. (2005). 5-lipoxygenase deficiency prevents respiratory failure during ventilator-induced lung injury. *Am J Respir Crit Care Med.* 172(3): 334-343.
23. Calandra T, Cohen J; International Sepsis Forum Definition of Infection in the ICU Consensus Conference. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. *Crit Care Med.* 2005 Jul;33(7):1538-48.
24. Calder, PC (2004). N-3 fatty acids, inflammation, and immunity--relevance to postsurgical and critically ill patients. *Lipids* 39(12): 1147-1161.
25. Carpenter, CT, Price, PV, et al. (1998). Exhaled breath condensate isoprostanes are elevated in patients with acute lung injury or ards. *Chest* 114(6): 1653-1659.
26. Cerra, FB, Benitez, MR, et al. (1997). Applied nutrition in icu patients. A consensus statement of the american college of chest physicians. *Chest* 111(3): 769-778.
27. Chaintreuil, J, Monnier, L, et al. (1984). Effects of dietary gamma-linolenate supplementation on serum lipids and platelet function in insulin-dependent diabetic patients. *Hum Nutr Clin Nutr.* 38(2): 121-130.

28. Chilton, FH, Patel, M, et al. (1993). Dietary n-3 fatty acid effects on neutrophil lipid composition and mediator production. Influence of duration and dosage. *J Clin Invest* 91(1): 115-122.
29. Chilton, L, Surette, ME, et al. (1996). Metabolism of gammalinolenic acid in human neutrophils. *J Immunol.* 156(8): 2941-2947.
30. Chollet-Martin, S, Rousset, F, et al. (1994). Cytokines in adult respiratory distress syndrome. *Lancet* 344(8934): 1440.
31. Cleland, LG, James, MJ, et al. (2003). The role of fish oils in the treatment of rheumatoid arthritis. *Drugs* 63(9): 845-853.
32. Cosgrove, JP, Church, DF, et al. (1987). The kinetics of the autoxidation of polyunsaturated fatty acids. *Lipids* 22(5): 299-304.
33. Cowley, HC, Bacon, PJ, et al. (1996). Plasma antioxidant potential in severe sepsis: A comparison of survivors and nonsurvivors. *Crit Care Med.* 24(7): 1179-1183.
34. Cracowski, JL, Tremel, F, et al. (2000). Increased formation of f(2)-isoprostanes in patients with severe heart failure. *Heart* 84(4): 439-440.
35. De Caterina, R, Cybulsky, MI, et al. (1994). The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. *Arterioscler Thromb* 14(11): 1829-1836.
36. De Jonghe, B, Appere-De-Vechi, C, et al. (2001). A prospective survey of nutritional support practices in intensive care unit patients: What is prescribed? What is delivered? *Crit Care Med* 29(1): 8-12.
37. DeMets, DL and Ware, JH (1982). Asymmetric group sequential boundaries for monitoring clinical trials. *Biometrika* 69: 661-663.
38. Dickerson, RN, Boschert, KJ, et al. (2002). Hypocaloric enteral tube feeding in critically ill obese patients. *Nutrition* 18(3): 241-246.
39. Dietrich, M, Block, G, et al. (2002). Antioxidant supplementation decreases lipid peroxidation biomarker f(2)-isoprostanes in plasma of smokers. *Cancer Epidemiol Biomarkers Prev.* 11(1): 7-13.
40. Donnelly, SC, Strieter, RM, et al. (1993). Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. *Lancet* 341(8846): 643-647.
41. Donnelly, SC, Strieter, RM, et al. (1996). The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. *Ann Intern Med* 125(3): 191-196.























163. Ware, LB and Matthay, MA (2000). The acute respiratory distress syndrome. *N Engl J Med.* 342(18): 1334-1349.
164. Wildhaber, BE, Yang, H, et al. (2005). Lack of enteral nutrition--effects on the intestinal immune system. *J Surg Res.* 123(1): 8-16.
165. Windsor, AC, Kanwar, S, et al. (1998). Compared with parenteral nutrition, enteral feeding attenuates the acute phase response and improves disease severity in acute pancreatitis. *Gut* 42(3): 431-435.
166. Wood, LG, Fitzgerald, DA, et al. (2000). Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma. *Lipids* 35(9): 967-974.
167. Yu, BP (2005). Membrane alteration as a basis of aging and the protective effects of calorie restriction. *Mech Ageing Dev.* 126(9): 1003-1010.